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 Abstract 
Introduction 
Colorectal cancer (CRC) is one of the most serious complications of colonic 
inflammatory bowel diseases. As with any disease, prevention is better than cure and there 
are several medications used for the condition itself or associated co-morbidity that are 
potential candidates for the chemoprevention of CRC.  
Aims 
• To scrutinise the available literature for the potential role of routinely prescribed 
medications for the chemoprevention of inflammatory bowel disease associated CRC 
(IBD-CRC).  
• To validate the use of the ResearchOne primary care database for use in healthcare 
research.  
• To describe the epidemiology of IBD-CRC cases in the ResearchOne primary care 
database.  
• To assess the role of routinely prescribed medications in the chemoprevention of 
IBD-CRC within ResearchOne. 
Methods  
Two systematic reviews and meta-analyses were conducted to assess the role of folate 
and aspirin or non-aspirin non-steroidal anti-inflammatory agents in the chemoprevention of 
IBD-CRC. To validate the ResearchOne database, one hundred and forty-seven patients were 
consented and recruited from hospital IBD clinics and their primary care record was 
compared with the hospital records. A descriptive analysis was made of the ResearchOne 
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IBD cohort and trends in numbers of IBD-CRC were explored. Finally, a series of nested 
case control studies were performed to assess the potential role of routinely prescribed 
medications in preventing CRC in those with IBD. Potential adverse associations with these 
medications were also explored. 
Results 
From the limited available evidence, non-aspirin non-steroidal anti-inflammatory 
medications (NA-NSAID) or aspirin use does not appear to be chemopreventative for CRC in 
patients with IBD. Following meta-analysis, folate prescription was negatively associated 
with the development of IBD-CRC (HR 0.58, 95% CI 0.37 to 0.80). Based on the validation 
study, the ResearchOne database appears a valid resource for healthcare research. These data 
showed that IBD diagnoses were recorded in 98% of patients, 93% had the correct IBD 
subtype, and 85% had the first date of diagnosis accurate to within 12 months. In a series of 
nested case-control studies using the ResearchOne database, 5-ASA medications (OR 0.32, 
95% CI 0.23 to 0.45), immunomodulators (OR 0.49, 95% CI 0.31 to 0.79), NA-NSAIDs (OR 
0.68, 95% CI 0.49 to 0.95), non-aspirin antiplatelets (OR 0.41, 95% CI 0.20 to 0.84), and 
statins (OR 0.55, 95% CI 0.37 to 0.81) were negatively associated with IBD-CRC. Statins 
showed a potential dose association with high dose drugs having a lower odds of IBD-CRC. 
Statin lipophilicity also was important with lipophilic, but not hydrophilic drugs having a 
significant association. Being prescribed a statin medication was significantly associated with 
a reduced number of steroid prescriptions, reduced need for surgical resection one year after 
diagnosis and reduced odds of being prescribed an immunomodulator medication one year 
after diagnosis.   
Conclusions 
- viii - 
CRC remains an important complication of IBD. The routine prescription of 5-ASA 
drugs, statins or folate supplementation may have a role in the chemoprevention of this 
disease.  Dedicated prospective studies in high-risk groups are now needed. The use of statins 
may have the additional benefit of controlling disease activity. 
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Chapter 1 
Introduction 
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Chapter 1: Introduction 
In this chapter I will discuss the problem of CRC in those with inflammatory bowel 
diseases. I will describe the epidemiology of the disease, and strategies that have been 
proposed to deal with it. I will highlight the level of evidence to date for chemoprevention 
using routinely prescribed medications and the possibilities for future work. I will then 
describe population datasets used in epidemiological research, including the ResearchOne 
primary care dataset. 
1.1 Inflammatory Bowel Diseases 
Inflammatory bowel diseases (IBD) are chronic diseases of the gastrointestinal tract 
with debilitating long-term sequelae and significant morbidity among those affected. The 
main types of IBD are ulcerative colitis (UC) and Crohn’s disease (CD). UC causes 
continuous inflammation from the rectum to varying extents in the colon. CD causes 
transmural inflammation of the small and large bowel. Due to the transmural inflammation 
CD can be complicated by fibrotic strictures, which in turn can lead to luminal obstruction, 
perforations, abscesses and fistulae.  A third category of IBD is indeterminate colitis, or IBD-
unclassified (IBD-U) where no definitive categorisation of IBD can be made. Over time, 
often with more histological evidence, these individuals may be further classified as either 
CD or UC.   
There is increasing evidence for genetic susceptibility to IBD. Contemporary studies 
have shown that 163 gene loci are associated with development of the diseases. (Jostins et al., 
2012) IBD develops in these genetically predisposed individuals who develop an altered 
immune response to gastrointestinal microbes after an environmental trigger. (Xavier and 
Podolsky, 2007) Established environmental associations with the disease are: cigarette 
smoking, appendicectomy, diet, psychological stress, and vitamin D. (Ananthakrishnan, 
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2015) There are differences for CD and UC, with smoking being positively associated with 
CD and negatively with UC.  
IBD can be diagnosed at any age, but most cases are diagnosed in childhood or early 
adulthood. (Loftus, 2004) There are modest sex differences with increased numbers of 
females being diagnosed with CD and a slight male predominance for UC. (Loftus, 2004) In 
the Western world the incidence of IBD started to rise rapidly in the mid-20th Century. At this 
time there was low prevalence of the disease. As IBD is typically diagnosed at a young age, 
has no known cure, and low mortality this has resulted in an exponential increase in 
prevalence of the diseases. (Ananthakrishnan, Kaplan and Ng, 2020) The combined 
prevalence of IBD is estimated at 396 per 100,000 population in the UK. (Stone, Mayberry 
and Baker, 2003) Recent population-based estimates from 2 large American insurance 
databases, encompassing over 60 million individuals, put the estimated prevalence at a higher 
rate at 478 per 100,000. This estimate translates to 1.2 million adults with the disease in the 
USA. (Ye et al., 2019) The prevalence of IBD is also increasing with the same study from 
American insurance populations showing a significant increase from 2007 to 2016 (Figure 1). 
The cost to the individual and healthcare systems of managing IBD in the Western world is 
considerable. There are increasing, expensive options in the treatment armamentarium for 
managing IBD, and as it affects people at working age the societal costs are large. In Europe 
there are an estimated 2.5 to 3 million people with IBD, with direct healthcare expenditure 
estimated at 4.6 to 5.6 billion euros. (Burisch et al., 2013).
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Figure 1 Trend in adult IBD prevalence in the USA between 2007 and 2016. (Ye et al., 2019) 
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The peak age of incidence of CD is the third decade and UC incidence rises from the 
second decade and plateaus soon after. (Bernstein et al., 1999)  
The precise aetiology of IBD remains unknown. There is a multifactorial development 
from an interaction between genetic susceptibility, environment, and immune dysfunction. 
Competing theories propose an abnormal immune response to a normal environment or an 
enhanced immune response to an abnormal environment. (Larabi, Barnich and Nguyen, 
2020)Established risk factors for the development of IBD are white ethnicity, female sex, and 
positive family history. Primary sclerosing cholangitis is strongly associated with the 
development of IBD, with up to 90% of those with the condition developing UC. (Broomé et 
al., 1995)   
In addition to the significant burden of illness affecting individuals in their prime 
productive years, the management of IBD is complex and resource intensive resulting in 
considerable health service use. (Hay and Hay, 1992) Hospital admission rates among 
patients with IBD, studied using the Hospital Episode Statistics (HES), showed that between 
1989/1990 and 1999/2000 age-standardised admission rates for CD rose by 14 percent whilst 
admissions for UC rose by 6 per cent. (Lloyd et al.) 
1.2 Colorectal Cancer in those with Inflammatory Bowel Diseases 
Colorectal cancer (CRC) is one of the most serious complications of IBD. It is one of 
the most feared complications for those suffering with the conditions. (Lopez et al., 2016) 
Significant resource is spent on methods to prevent its development, detect early lesions and 
improve mortality.  There are international guidelines on screening and surveillance for CRC 
in those with IBD from Britain (Cairns et al., 2010), Europe (Van Assche et al., 2013) and the 
United States, (Farraye et al., 2010)  as well as an international collaboration and consensus 
statement in 2015. (Laine et al., 2015) Despite these resources and guidelines there is still 
some uncertainty about the current population risk of CRC, which groups should be 
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surveyed, the best method for surveillance, and the optimal interval between investigations. 
There is also a lack of evidence that surveillance prevents mortality in this population. (Bye 
et al., 2017) 
1.3 Pathogenesis of IBD CRC 
Cancer in the gastrointestinal tract results from several changes in epithelial cells. One 
of the first steps is often metaplasia, which is the change from one defined epithelium cell to 
another. (Humphries and Wright, 2008) This epithelium can be unstable and can further 
develop to dysplasia, the distortion of normal tissue architecture and cells. (Humphries and 
Wright, 2008)  
There is accumulating evidence that cancers develop from a stem cell that 
accumulates the required genetic alterations for malignant potential. (Barker et al., 2009) 
This, cancer stem cell concept, (Clarke et al., 2006) suggests that a small number of these 
stem cells are able to divide and support a tumour.  
The colonic mucosa is comprised of millions of finger like projections of epithelial 
cells called crypts. At the base of the crypts are a number of stem cells, which form the 
population of cells in the crypt lining. In certain environments stem cells can be lost resulting 
in one dominant cell lineage, called monoclonal cell expansion. For the number of crypts to 
increase during colon growth and development, or after destruction due to an insult such as 
colonic inflammation there needs to be a process of forming new crypts. This is called crypt 
fission, (Greaves et al., 2006) whereby one crypt is able to divide forming new identical 
crypts.   If this is from an abnormal crypt with monoclonal cell lineage, the daughter crypts 
will have the same monoclonal lineage. This is the mechanism by which a single mutated cell 
lineage can expand to form a dysplastic lesion. The process usually takes many months to 
proceed but may be increased in inflammatory states with increased cell turnover. This is one 
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of the proposed mechanisms for the rapid growth of IBD-CRC. (Humphries and Wright, 
2008; Wong et al., 2002)  
IBD -associated CRC shares some similar molecular pathways with sporadic CRC, 
however there are also clear differences. Sporadic CRC develops along an adenoma – 
dysplastic polyp – malignancy sequence, with early loss of function of the adenomatosis 
polyposis coli (APC) tumour suppressor gene. (Vogelstein et al., 1988) The cellular 
mutations that occur later in sporadic CRC, such as loss of p53, occur much earlier in IBD 
CRC, (Leedham et al., 2009) with the loss of APC gene function occurring much later. This 
sequence of events may also progress much faster in IBD associated CRC. 
Inflammation has been linked with cancer development. Various cytokines and 
chemokines are intimately involved with tumour growth and development. Tumour necrosis 
factor alpha (TNFα) is an inflammatory mediator whose expression is enhanced in several 
cancers including CRC and has been implicated in inflammatory infiltration, tumour 
angiogenesis, migration and invasion. (Waters, Pober and Bradley, 2013) Chronic 
inflammation is believed to be one of the main factors that drives carcinogenesis in IBD, 
which in turn leads to abnormal cell growth and DNA damage. (Murthy, Flanigan and 
Clearfield, 2002; Ullman and Itzkowitz, 2011)  
Animal studies have shown that both the initiation and progression of neoplasia can 
be stimulated by inflammation. (Itzkowitz and Yio, 2004) Inflammation may play its role in 
carcinogenesis by exerting a “field effect” on the colonic mucosa. Analysis of mucosal 
specimens has shown that some of the molecular changes leading to carcinogenesis such as 
p53 mutations, (Brentnall et al., 1994) chromosomal, (Rabinovitch et al., 1999) and 
microsatellite instability (Willenbucher et al., 1999) can be present before the development of 
dysplasia, i.e. microscopically normal cells,  or in areas of non-dysplastic colon in a patient 
with co-existing dysplasia or cancer.     
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Figure 1. Carcinoma sequence pathways for IBD associated colorectal cancer and sporadic colorectal cancer. (Matkowskyj et al., 
2013) 
 
The inflammatory bowel disease (IBD)–associated colorectal cancer pathway. Molecular changes in p53, followed by chromosomal instability, and finally b-catenin/WNT 
signalling (A). The adenoma-carcinoma sequence established in 1988 by Vogelstein (Vogelstein et al., 1988) as a stepwise progression of mutational activation of oncogenes 
and inactivation of tumour suppressor genes, resulting in cancer (B). Abbreviations: MSI, microsatellite instability.
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1.4 Field carcinogenesis 
The field carcinogenesis theory proposes that environmental and genetic factors 
contribute to a favourable environment for dysplasia and malignancy to develop. When 
synchronous (occurring at the same time) cancers are discovered they often share similar 
genetic mutations with each other. Field carcinogenesis is already well recognised in clinical 
practice for CRC. The risk of a proximal CRC is predicted by findings in the distal colon on 
sigmoidoscopy. (Imperiale et al., 2000; Levin et al., 1999) Patients with no lesions in their 
left colon are less likely to have right sided lesions as they have a less favourable colonic 
environment for carcinogenesis. The field carcinogenesis effect would explain some of the 
higher rates of synchronous, and metachronous (subsequent) cancers in patients with IBD.   
Areas for potential improvement in early detection of IBD-CRC, may come in the 
identification of mutations and markers to identify those at greater risk of CRC. For sporadic 
colorectal cancer, optical detection of chromosomal instability, microsatellite instability and 
DNA methylation patterns are being developed with a view to using to them to risk-stratify 
patients. (Backman and Roy, 2013) It is worth bearing in mind, however that prospective 
studies of the effectiveness of these markers would be challenging in the IBD population due 
to the lower number of cases overall. 
1.5 How IBD colorectal cancer differs from sporadic colorectal cancer 
Those with IBD are at higher risk of synchronous and metachronous CRC. In a 
retrospective, single-centre series of surgical resections from patients with UC, 55% of 
specimens harboured synchronous dysplasia whilst 14% had synchronous malignancy. (Kiran 
et al., 2010) In a population study in the USA in 2012, there was a significantly greater 
number of metachronous malignancies in patients with IBD compared to those previously 
diagnosed with sporadic CRC (17% vs 12% respectively) (Gearhart et al., 2012)  
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IBD-CRC has worse outcomes than sporadic cancer. In a population analysis of 
individuals over the age of 65 in the US, cancer specific survival was worse for IBD-CRC 
than for sporadic counterparts with a mean survival of 33 months compared to 42 months. 
(Gearhart et al., 2012)  
1.6 Epidemiology of IBD-CRC 
Individuals with IBD are at increased risk of developing CRC, compared to those 
without the diseases. A landmark analysis for the increased risk came from Eaden et al in 
2001. (Eaden, Abrams and Mayberry, 2001) Here, a cumulative incidence of 2% at 10 years 
and 8% at 20 years of follow-up was shown.  There is now evidence that these estimates may 
have been overstated, but pooled population data still suggests an increased risk in UC with a 
pooled standardised incidence ratio of 2.4 (95% CI, 2.1 to 2.7). (Jess, Rungoe and Peyrin-
Biroulet, 2012) Duration of the disease still appears to be one of the most important risk 
factors, the latest meta-analysis estimating the population risk of CRC in IBD at 0.8%, 2.2% 
and 4.5% after 10, 20 and >20 years of disease respectively. (Lutgens et al., 2013) For 
Crohn’s colitis the risk of CRC is probably slightly lower than that for UC, the latest meta-
analysis of population based studies reporting a standardised incidence ratio of 1.7 (95% CI, 
1.01–2.5). (Lutgens et al., 2013) 
1.7 Temporal trends of CRC in those with IBD 
There have been recent conflicting data on whether the risk of IBD-CRC is declining. 
Studies from Sweden (Söderlund et al., 2009) and the USA (Herrinton et al., 2012) have 
reported an increase in IBD-CRC. A 2012 population-based study in Denmark has suggested 
a lower incidence of CRC than previously seen in patients with UC, and similar levels as the 
general population for patients with Crohn’s colitis. (Jess et al., 2012) Contemporary 
evidence, from the largest cohort to date of ~96,000 individuals with UC from Sweden and 
Denmark showed an increased risk of CRC and death from CRC. The magnitude of the risk 
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is falling, but is still increased compared to a matched cohort from the general population. 
(Olén et al., 2020)  
There are several potential reasons for a possible decline in CRC in this population. 
As colonic inflammation is one of the most strongly associated factors, better control of 
disease activity should plausibly reduce the malignant potential. There has also been a 
dramatic increase in the use of diagnostic tests in patients with IBD including colonoscopy, 
whether as a dedicated screening or surveillance procedure, or not.  These tests may detect 
dysplasia, or pre-malignant polyps or lesions which may be removed that could reduce the 
number of incident cases of CRC. There has also been an increase in cross-sectional imaging 
in the form of computed tomography (CT) or magnetic resonance imaging (MRI) in these 
patients. This may also detect pre-malignant lesions that are removed and prevent subsequent 
CRC. Of course, the increase in investigations may also inflate the risk as cancers are 
diagnosed that would otherwise not have been detected.  
Having considered these factors we must also bear in mind that there has been a 
decline in surgical interventions, such as pan-proctocolectomy in colitis patients. (Frolkis et 
al., 2013) This could have important implications over the coming years as it is likely that 
these patients, who would have been operated on, are at the greatest risk of CRC. These are 
individuals with the most severe, extensive disease, who are now aggressively managed with 
anti-inflammatory and immunosuppressive medications. They are more likely to have chronic 
inflammation, pseudopolyps, inflammatory polyps and colonic strictures which have all been 
associated with increased IBD-CRC risk. (Rutter et al., 2004a, 2004b) They are also 
receiving immunosuppressive medication that could adversely affect host anti-neoplastic 
mechanisms. 
1.8 Risk factors for CRC in IBD 
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There are established risk factors for the development of colitis associated CRC. As 
mentioned, the duration of colitis is important and an increased risk after 10 and 20 years of 
disease has been consistently shown in studies from both referral and population cohorts. 
(Eaden, Abrams and Mayberry, 2001)  There is however a high rate of cancers that develop 
earlier in the course of IBD as shown by a Netherlands population database study. (Lutgens et 
al., 2008) Here, 22% of cancer cases were diagnosed before 8 years, which is the cut-off for 
the start of routine screening in international guidelines. (Itzkowitz and Present, 2005)  
The extent and activity of colitis are also implicated in the risk of developing CRC. 
Inflammation beyond the left side of the colon is associated with a 4.8 fold increase in the 
risk (Jess et al., 2005) and in a case-control study from a US referral population, histological 
inflammation was independently shown to increase the odds of developing CRC (OR 3.68; p 
< 0.001). (Rubin et al., 2013) Disease extent ≥ 50% of the colon is also associated with 
increased risk of CRC. (Lutgens et al., 2014) 
As with sporadic CRC, previous colonic dysplasia is also associated with future 
cancer risk. A meta-analysis of surveillance studies reported a nine-fold increase in the odds 
of developing cancer (OR 9.0, 95% CI: 4.0 to 20.5) when low grade dysplasia is detected on 
colonoscopy. (Thomas et al., 2007)  
As well as the clinical features of the colitis, there are markers found at endoscopy 
that have been shown to predict the future risk of malignancy. Post-inflammatory polyps 
develop at the site of prior disease activity and mucosal inflammation. A United Kingdom 
referral centre study showed that the presence of these polyps was a marker for increased 
CRC (OR 2.14, 95% CI 1.24 to 3.70). (Rutter et al., 2004b) These polyps are not thought to 
have malignant potential (Kelly and Gabos, 1987) but are a marker of chronic disease activity 
and those at greater risk of CRC due to chronic inflammation.  They also can make the 
detection and removal of subtle lesions more difficult. This makes the colon more 
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challenging to survey endoscopically so some pre-cancerous lesions, which could be 
removed, may be missed. As a result of these findings patients with multiple post-
inflammatory polyps are advised to consider prophylactic colectomy in British society of 
gastroenterology (BSG) guidelines. (Cairns et al., 2010) Colonic strictures are also a poor 
prognostic endoscopic marker. From the same UK study such strictures were associated with 
an increase in the odds of developing CRC (OR 4.22, 95% CI 1.08 to 15.54). These strictures 
may be malignant themselves or be a marker of acute or chronic inflammation. Another 
important risk factor that has been consistently shown to be associated with colitis associated 
CRC is co-existent IBD and primary sclerosing cholangitis (PSC). (Broomé et al., 1995; 
Soetikno et al., 2002; Claessen et al., 2009) 
When considering an individual risk profile, and the need for colonic surveillance, it 
is important to consider potential protective factors. A macroscopically normal colonoscopy 
is associated with a reduced chance of developing future CRC (OR 0.38; 0.19 to 0.73). 
(Rutter et al., 2004a) 
1.9 Surveillance Colonoscopy for IBD related CRC 
The goal of surveillance procedures is to detect early lesions to improve mortality 
from the disease. The number of colonoscopy procedures performed has increased 
dramatically in both the general population and individuals with IBD. This could lead to the 
detection of pre-malignant lesions, or early cancers that are more amenable to endoscopic or 
surgical resection and have better outcomes. This protective effect is recognised in sporadic 
CRC. (Nishihara et al., 2013) 
There is considerable cost to both the individual and healthcare provider with regular 
surveillance colonoscopies, especially as colitis is often diagnosed at a young age. With 
certain risk factors, such as co-existent PSC, patients should be offered annual surveillance 
tests. The challenge is to identify those who are at the greatest risk and would benefit most 
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from surveillance tests, detect early dysplastic lesions that can then be either removed 
endoscopically or referred for surgical management. Issues that must be considered are the 
demand for the service, uptake from patients, how surveillance should be performed and what 
should be done if dysplasia or malignancy is detected. 
1.9.1 Surveillance methods 
Colonoscopy is the principal investigation used for the surveillance of IBD-CRC. 
Historically, multiple sequential biopsies were taken from the colonic mucosa to sample for 
invisible dysplasia. It is estimated that to achieve 90% detection of dysplasia 30-40 biopsies 
are necessary. (Ullman, 2005)  Colonoscopy with pan-colonic dye spray, or 
chromoendoscopy is a method to try and improve dysplasia and cancer detection in IBD. This 
technique uses the application of dye to the colon wall via a spray catheter through the water 
jet channel of the colonoscope during the withdrawal of the instrument. The dyes that are 
used are typically methylene blue or indigo carmine. Application of the dye enhances subtle 
changes in the colon mucosa that can then be more easily detected, biopsied or removed.   
A systematic review and meta-analysis in 2019 of six randomised controlled trials 
(RCTs), and separately non-randomised observational studies, incorporating 10 studies in 
total showed chromoendoscopy was associated with detecting significantly more dysplasia 
than white-light endoscopy (RR 1.5, 95% CI 1.08 to 2.10), but not when compared to high-
definition white light endoscopy (RR 1.36, 95% CI 0.84 to 2.18). (Feuerstein et al., 2019)  
Non-randomised studies showed a significant benefit for chromoendoscopy over both 
standard definition (RR 3.53, 95% CI 1.38 to 8.99) and high-definition white-light endoscopy 
(RR 3.15, 95% CI 1.62 to 6.13). 
1.9.2 Current Surveillance Guidelines 
CRC in IBD arises from dysplasia and progresses along an inflammation-dysplasia- 
malignancy pathway. In 2015 an international, multidisciplinary group convened to discuss 
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surveillance in IBD and drew up the SCENIC consensus guidelines. (Laine et al., 2015) 
There have been similar efforts from the European Crohn’s and Colitis Organisation, (Van 
Assche et al., 2013) American Gastroenterology Society (Farraye et al., 2010) and the BSG, 
who published updated guidelines in 2010. (Cairns et al., 2010) The guidelines are consistent 
in their recommendations for regular colonic surveillance in high risk individuals, with the 
BSG recommending intervals of 1 year, 3 years, 5 years or no surveillance depending on the 
presence of certain risk factors (Figure 2).
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Figure 2 British Society of Gastroenterology colitis surveillance guidelines, Cairns 2010 (Cairns et al., 2010) 
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1.10 Efficacy of Surveillance 
In the general population, colonoscopy is effective in reducing the incidence and 
mortality from colorectal cancer through the detection and removal of pre-cancerous lesions 
and identifying early cancers that will be more amenable to treatment. (Nishihara et al., 2013) 
Individuals with colitis can be excluded from the UK bowel cancer screening programme due 
to the risk of a false positive stool-based blood screening test. Furthermore, even though there 
are societal guidelines advocating surveillance in the IBD population, there is no dedicated 
screening and surveillance programme for this group of patients.  
There is sparse evidence of the efficacy of surveillance colonoscopy in the IBD 
population. Early reports showed no benefit from surveillance with random colonic biopsy, 
hampered by 40% non-attendance. (Lynch et al., 1993) Later studies from the 1990’s 
suggested a potential benefit to surveillance. (Haggittii et al., 1993; Karlén et al., 1998) A 
recent study by Ananthrakrishnan et al. in 2014 explored the effects of colonoscopy on CRC 
incidence and survival from a US tertiary care population of patients with IBD. 
(Ananthakrishnan et al., 2014) Here, having a colonoscopy within 36 months was associated 
with a reduced likelihood of CRC (OR 0.56; 95% CI 0.39 to 0.80). Colonoscopy within the 6-
36 months before diagnosis was also independently associated with reduced all-cause 
mortality (OR 0.34; 95% CI, 0.12 to 0.95) suggesting that the tests were effective in detecting 
early, treatable malignancies.  
Further evidence for the use of surveillance colonoscopy came from the analysis of 
surveillance data from St Mark’s Hospital in London. After analysing over 40 years of cohort 
data they showed increased detection of dysplasia and early cancers, reduced advanced 
cancer and a reduced colectomy rate for those undergoing surveillance. (Choi et al., 2015b) A 
Cochrane review of the efficacy of surveillance was conducted in 2017, and summarised the 
available evidence. (Bye et al., 2017) This included five observational studies and concluded 
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that there was less CRC following surveillance (1.83% vs 3.17%), less CRC related death 
(8% vs 22%), and more early CRC (16% vs 8% Duke’s A or B). The overall quality of the 
included studies was graded as very low for all of the outcomes. Caution should be applied to 
any conclusions from this evidence and more work is needed.  
We need to bear in mind that the reduction seen in incidence and mortality is an 
association and not necessarily a result of the colonoscopy. Other factors could be responsible 
for the reduction such as associated healthy behaviours, adherence to medications and more 
judicious reporting of red-flag symptoms in those patients who are more likely to attend for 
colonoscopy. For ethical and logistical reasons, a randomised controlled trial on surveillance 
colonoscopy is unlikely to be performed so we will have to rely on well-designed, 
retrospective population-based studies that can adjust for known risk factors and account for 
those who may not attend for screening and surveillance procedures. 
1.11 Post-Colonoscopy Colorectal Cancer 
Post-colonoscopy colorectal cancers (PCCRC) have been proposed as a key quality 
indicator of colonoscopy. (Kaminski et al., 2010) These tumours can either be due to a lesion 
that was not detected on the previous colonoscopy, or more rarely a rapidly growing 
malignancy. (Tollivoro et al., 2018) Studies from sporadic colorectal cancer have shown that 
these cancers are more likely to be in the right colon, more common in women, in older 
individuals and when procedures are not performed by experienced endoscopists.  A recent 
population-based UK study has shown that the rate of CRC in the 6 to 36 month period 
following a colonoscopy is 7.4%. (Burr et al., 2019) The PCCRC-3yr rate for those with IBD 
was more than five times that of the general population at 36%.  (Burr et al., 2019) Despite a 
significant improvement in PCCRC-3yr rates in people without the disease from 9% for 
colonoscopies in 2005 to 6.5% in 2013, the PCCRC-3yr rate in people with IBD remained 
constant throughout the study period (p=0.24). 
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A study by Wang et al in 2013 (Wang et al., 2013) showed that the rate of early or 
missed CRC in older patients was almost three times as high for patients with IBD compared 
with non-IBD patients, 5.7% for non-IBD patients, 15.1% for Crohn’s disease and 15.8% for 
ulcerative colitis (p<0.001). These cancers were also less likely to be right sided (p<0.05). 
There should be some caution in interpreting this data as cancers in the older population are 
not likely to be representative of the whole age range of individuals with IBD.  
There are several important considerations for the high rate of PCCRC in IBD. 
Firstly, as already explained CRC in IBD is different to sporadic CRC. The differences could 
account for more aggressive, fast growing cancers that occur within three years of a normal 
endoscopic test. Secondly, we know that post-inflammatory polyps and strictures are 
associated with increased incidence of cancer. These findings could either be misclassified as 
benign or distract the endoscopist from subtle lesions with dysplastic or malignant cells. 
Alternatively, the reason for not detecting pre-malignant lesions could plausibly be due to the 
fact that they can be flat and subtle adenomas requiring experience for detection. (Torres, 
Antonioli and Odze, 1998)  
It is important to consider these high rates of PCCRC because attending for a 
colonoscopy and having a normal result is reassuring to both patients and clinicians. Patients 
may be less inclined to report symptoms at an early stage after a colonoscopy as usually they 
have observed the test, not seen a lesion and been reassured after the procedure that 
everything was normal. 
1.12 Post-Colectomy Colorectal Cancer 
Colectomy markedly reduces the future cancer risk. After undergoing a 
proctocolectomy and ileal pouch anal anastomosis there is a residual cancer risk of 0.5%. 
(Derikx et al., 2016) For those with an intact rectal stump the rate is 2%. (Derikx et al., 2016) 
One of the most important risk factors for future cancer risk seems to be the presence of 
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neoplasia before a resection. This would be in line with the “field carcinogenesis” theory 
described earlier. These patients should be considered in surveillance guidelines.  
1.13 Chemoprevention of IBD associated CRC 
As with any disease, prevention is better than cure. In the general, non-IBD 
population, there is the potential for chemoprevention against the development of sporadic 
adenomas and CRC. (Arber et al., 2008) For CRC in patients with inflammatory bowel 
disease, medications that are used to control luminal inflammation appear to have a protective 
effect with 6-mercaptopurine, azathioprine or methotrexate being associated with a reduced 
risk of developing CRC (OR 0.35; p< 0.01), (Rubin et al., 2013)  Anti-TNF-α medications 
were not included in this study. 5-aminosalicylate (5-ASA) medications are the most 
prescribed medications for UC and colonic CD. For 5-ASA medications there has been 
conflicting evidence with some, but not all, studies showing a protective association. A meta-
analysis by Velayos et al. including nine studies showed a 49% reduction in the odds of 
developing CRC (OR 0.51, 95% CI 0.37 to 0.69). (Velayos, Terdiman and Walsh, 2005) 
However, a meta-analysis of non-referral patients did not show a protective association (OR 
0.95, 95 % CI 0.66 to 1.38). (Nguyen, Gulamhusein and Bernstein, 2012) There is generally a 
lack of research on the protective effects of other commonly prescribed medications that have 
a plausible biological role in chemoprevention against CRC. These include aspirin, 
(Flossmann and Rothwell, 2007) antiplatelet agents, non-aspirin non-steroidal medications 
(NA-NSAID), (Papagiorgis, 2015) statins, (Poynter and Gruber, 2005) calcium channel 
blockers, (Newmark, Wargovich and Bruce, 1984) and folate supplementation. (Mouzas, 
Papavassiliou and Koutroubakis, 1998) 
1.13.1 The role of NSAIDs in the chemoprevention of CRC 
There are plausible biological mechanisms for how NSAIDs may prevent CRC. 
NSAIDs inhibit cyclo-oxygenase-2 (COX-2) enzyme function which has been implicated in 
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several carcinogenic pathways including promoting tumour angiogenesis and inhibition of 
apoptosis. Laboratory studies have reported an over expression of COX-2 in CRC cells and 
COX-2 inhibitors prevented CRC cell growth in-vitro. (Dixon et al., 2013) 
Several epidemiological studies have extolled the potential role for NSAIDs in 
preventing many solid tumours including: prostate, (Dasgupta et al.) oesophageal, (Duan et 
al., 2008) breast, (Agrawal and Fentiman, 2008) lung, (Harris, Beebe-Donk and Alshafie, 
2007) ovary, (Bonovas, Filioussi and Sitaras, 2005) and hepatobiliary. (Grainge et al., 2009) 
One of the most consistent findings is that regular use of NSAIDs is associated with lower 
incidence of CRC (Vinogradova et al., 2007) and adenomatous polyps. These associations 
have also been observed in randomised controlled trials of NSAIDs in those with familial 
adenomatous polyposis syndrome, and high-risk of developing CRC, where treatment with 
sulindac resulted in regression in size and reduced numbers of adenomatous polyps. 
(Giardiello et al., 2002, 1993) 
1.13.2 Aspirin  
There are several plausible biological mechanisms for how aspirin use may prevent 
adenomatous polyp formation and CRC. The potential role in chemoprevention is likely to be 
through several integrated pathways rather than one mechanism in tumour prevention. (Drew, 
Cao and Chan, 2016) Aspirin works as an anti-inflammatory and antiplatelet agent. Its 
principal mechanism of action is through inhibiting rate limiting steps in the conversion of 
arachidonic acid to prostaglandins and eicosanoids namely: PGE2, PGD2, PGF2, thromboxane 
A2, and prostacyclin. (Drew, Cao and Chan, 2016) This is achieved through irreversible 
modification of cyclo-oxygenase (COX) enzymes. COX-2 is expressed in many tissues, and 
is overexpressed in CRC cells. (Dixon et al., 2013) The COX enzymes promote cell division, 
tumour angiogenesis and reduced cell death (apoptosis). Increased prostaglandin E2 (PGE2) 
promotes carcinogenesis, and is seen in CRC cells. (Dixon et al., 2013; Pugh and Thomas, 
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1994)  Another potential target for aspirin is through its effect on WNT-β-catenin signalling. 
Alteration of WNT signalling is seen in CRC. (Fearon, 2011) Aspirin modulates WNT 
signalling at multiple levels, including COX-2 and PGE2 pathways, and the expression of key 
WNT target genes involved in CRC carcinogenesis. (Gala and Chan, 2015) 
There is strong evidence supporting the potential role for aspirin in preventing 
sporadic CRC. (Dehmer et al., 2016; Flossmann and Rothwell, 2007) A consistent finding 
that has been observed in many observational studies. A meta-analysis, including over 9,000 
individuals showed a 41% reduction in CRC risk for aspirin users (RR 0.59, 95% CI 0.54 to 
0.64). (Cuzick et al., 2009) More recently Rothwell et al, analysed ~14,000 patients from 
RCTs investigating aspirin use and cardiovascular protection followed up for 20 years and 
found a reduced incidence of CRC (HR 0.76, 95% CI 0.60 to 0.96), and reduced mortality 
from CRC (HR 0.65, CI 0.48 to 0.88). (Rothwell et al., 2010a) There are also prospective 
data that aspirin is may prevent CRC after secondary analysis of trials investigating aspirin 
for prevention of cardiovascular disease. A meta-analysis of 3 such studies, analysing 
secondary data from prospective trials investigating aspirin for the prevention of 
cardiovascular disease showed that aspirin at a dose between 75 and 300mg reduced CRC 
risk significantly (HR 0.75, 95% CI 0.56 to 0.97). (Rothwell et al., 2010b) On the back of this 
compelling evidence, the United States Preventative Services Task Force have recommended 
aspirin as primary prevention against CRC for those aged between 50 and 60 years with 
greater than 10%, ten-year cardiovascular disease risk. (Bibbins-Domingo and U.S. 
Preventive Services Task Force, 2016) 
1.13.3 Role of statins in chemoprevention of CRC 
The 3-hydroxy-3methylglutaryl-coenzyme-A reductase inhibitors (statins) are a class 
of drug that were first identified in the 1970’s, and have been approved for the treatment of 
hypercholesterolemia since the 1980’s. (Oates, Wood and Grundy, 1988) Statins are used in 
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the primary and secondary prevention of cardiovascular disease and are one of the most 
widely prescribed medications in the world with up to 44% of American adults over the age 
of 65 years being prescribed them.   HMG-CoA is involved in cholesterol synthesis, 
catalysing the rate limiting step in the mevalonate pathway. Mevalonate is a fatty acid which 
is essential in the biosynthesis of cholesterol and is formed from HMG-CoA by HMG-CoA 
reductase.  Inhibition of HMG-CoA reductase by the small molecule statins, reduces 
cholesterol synthesis, resulting in lower levels of low-density lipoprotein cholesterol (LDL). 
(Demierre et al., 2005) 
In addition to lowering cholesterol levels, statins have many potential 
chemopreventative effects through inhibition of the cell cycle, induction of apoptosis, 
inhibition of cytokines which can cause inflammatory tumours to proliferate, inhibition of 
tumour angiogenesis and suppression of tumour growth. (Katz, 2005) The mevalonate 
pathway is also up-regulated by a mutated p53 tumour suppressor gene, which is common in 
CRC. (Nielsen, Nordestgaard and Bojesen, 2012) 
Statins have been shown to block tumour growth and proliferation in vitro, (Agarwal 
et al., 1999; Wächtershäuser, Akoglu and Stein, 2001) and statin use is associated with 
reduced incidence of many solid state tumours including: breast, (Ahern et al., 2011) prostate, 
(Platz et al., 2006) oesophageal, (Alexandre et al., 2014) and recently hepatobiliary cancers. 
(Liu et al., 2018) For sporadic CRC, a meta-analysis of 42 studies showed that statin use was 
associated with a modest reduction in the risk of developing CRC (RR 0.90, 95% CI 0.86 to 
0.95). A meta-analysis of 6 studies including 13, 239 patients also showed a significant 
negative association between statin use and the development of CRC and advanced adenomas 
(RR 0.83, 95% CI 0.75 to 0.93). (Jung et al., 2016) Statin use, after a diagnosis of CRC is 
also associated with reduced CRC-specific mortality (adjusted HR 0.71, 95% CI 0.61 to 
0.84). (Cardwell et al., 2014) Furthermore, a recent cohort study from Hong Kong has shown 
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that statins are associated with a significant reduction in PCCRC-3yr (HR 0.72, 95% CI 0.55 
to 0.95). (Cheung et al., 2019) 
1.13.4 Role of Antiplatelets in the chemoprevention of CRC 
There is a much smaller body of evidence investigating whether antiplatelet agents, 
other than aspirin, have a chemopreventative effect on solid tumours.  
Platelet function is principally for thrombosis and haemostasis but there is increasing 
experimental and epidemiological evidence for their role as amplifiers of chronic 
inflammatory processes. Over the past 20 years there has been accumulating evidence for the 
role of platelets in the direct stimulation of an inflammatory response. (Wecksler, 1992) The 
mechanisms for platelet derived inflammation are through the release of pro-inflammatory 
mediators including: platelet aggravating factor (PAF), Thromboxane A2, 12-
hydroxyeicosatetraenoic acid (12-HETE), platelet derived growth factor (PDGF), 
intracellular platelet factor 4 (IPF-4) and transforming growth factor beta (TGF-β). (Collins 
and Rampton, 1997)  A “reactive thrombocytosis” comprising a rise in platelet number, with 
changes in morphology and function is a marker of disease activity in chronic inflammatory 
conditions, including IBD. Patients with IBD are at risk of systemic thromboembolism with 
incidence ranging between 2 and 8%, rising to between 39 and 41% in post-mortem studies. 
(Murthy and Nguyen, 2011; Yuhara et al., 2013)  
To date there is a lack of dedicated research on the potential role of antiplatelet agents 
as anti-inflammatory agents in IBD.  They may also have a role in protecting against the 
development of IBD-CRC. As already discussed, IBD-CRC is likely to develop because of 
uncontrolled mucosal inflammation so as with other potential chemopreventative 
medications, if the inflammation is controlled then cancer might be prevented. 
1.13.5 Role of folate in chemoprevention of CRC 
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Folate (vitamin B9) is the generic term for a group of compounds, including folic acid 
as a supplement, that are essential for numerous bodily functions. (Scaglione and Panzavolta, 
2014) Folate deficiency in humans causes neural tube defects in embryos and megaloblastic 
anaemia in adults. Humans cannot synthesise folate, so it is obtained from foods such as leafy 
green vegetables, folic acid in supplements or food fortification, mandatory in the United 
States and Canada since 1998. There is a proposal for mandatory flour fortification in the UK 
that is under Government review. Folate has a role in DNA methylation and purine and 
thymidine synthesis for DNA and RNA (Choi and Mason, 2000) and folate deficiency has 
been implicated in carcinogenesis through permitting increased DNA damage and altering the 
expression of critical tumour suppressor and proto-oncogenes. (Kim, 1999) This is supported 
by experimental studies in rat models where folate deficiency has been shown to induce 
colorectal cancer and folate supplementation inhibits it. (Cravo et al., 1992; Kim et al., 1996) 
There is evidence for a “dual role” of folate in carcinogenesis whereby folate may prevent 
early cancers but causes harm if these lesions have formed. (Kim, 2007; Ulrich and Potter, 
2006) These studies, in colorectal mouse models, showed that high levels of folate promoted 
carcinogenesis once microscopic, neoplastic foci had developed. (Song et al., 2000a, 2000b) 
In spite of this, epidemiological studies have shown that reduced folate levels are 
associated with the development of several solid tumours including cervical, breast, pancreas, 
lung and colorectal cancer. (Freudenheim et al., 1991; Wien et al., 2012) Some of the most 
compelling evidence is for the potential protection against CRC, a recent meta-analysis of 27 
papers showed a relative risk estimate reduction of 0.85 (95% CI 0.74 to 0.99) when 
comparing low vs high folic acid supplementation. (Kennedy et al., 2011)  Patients with IBD 
are at increased risk of folate deficiency through inadequate nutritional intake, excessive 
intestinal loss and reduced absorption due to competitive inhibition by sulfasalazine use. 
(Potack and Itzkowitz, 2008; Swinson et al., 1981) 
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1.14 Potential adverse effects of chemoprevention agents 
As well as the potential benefits for chemoprevention there are concerns about 
potential negative effects of aspirin and the NA-NSAIDs on the lower gastrointestinal tract. 
Adverse effects of NA-NSAIDs on the colon include a NSAID colonopathy with diaphragm-
like stricturing and mucosal inflammation and ulceration, complicated diverticular disease 
including bleeding, (Strate et al., 2011) and microscopic colitis. (Laine et al., 2003; Abir et 
al., 2005) A possible association between the use of NSAIDs including aspirin and the onset 
or relapse of IBD has been repeatedly suggested. However, lack of controlled prospective 
trials make it difficult to draw definite conclusions. (Kefalakes et al., 2009; Maiden et al., 
2005)  
Aspirin use is associated with several side effects. The main concern is the risk of 
upper gastrointestinal bleeding and haemorrhagic stroke. Most studies using aspirin have not 
shown increased death rates from gastrointestinal bleeding suggesting that any bleeds related 
to aspirin are small and relatively insignificant. (Elwood P.C. Mustafa M. Almonte M. 
Morgan, 2012) 
1.15 Primary care datasets in healthcare research 
Electronic health records from primary care databases (PCD) are an important 
resource for healthcare research. The value of the databases for research purposes stems from 
the availability of information on “population-wide” data over a long period with detailed 
information on diagnoses and medication usage.  There are many PCD databases available in 
the UK that have been validated and are widely used for healthcare research. These include 
the Clinical Practice Research Datalink (CPRD, formerly GPRD), QResearch and The Heath 
Improvement Network (THIN). (de Lusignan and van Weel, 2006; Horsfall, Walters and 
Petersen, 2013; Thiru, Hassey and Sullivan, 2003) They are becoming increasingly popular in 
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healthcare research with over 1,500 publications resulting from the CPRD alone since its 
inception.  
1.15.1 GP coding 
In the UK a new GP contract, incorporating a novel quality and outcomes framework 
(QOF), was introduced in 2004. This payment-by-results scheme required GPs to produce 
annual reports on several quality indicators to receive supplementary payments. Data items 
relating to conditions included in the QOF were prioritised and coded diligently to generate 
financial rewards for the GP practice. Studies have shown that pre- and post- contract 
recording changed to reflect the data items within QOF. (Campbell et al., 2009) There is 
therefore the potential that a disease not included in the GP contract may not be as accurately 
coded as those included in QOF. Another important point when considering GP coded entries 
is that they do not contain “rule out” codes which would override previous entries. As such it 
is possible that some patients may be misclassified if diagnoses have been subsequently 
updated. Patients may have two different entries for the same condition where diagnoses have 
been subsequently revised after addition of subsequent clinical information. 
1.15.2 The ResearchOne primary care database 
ResearchOne is a relatively new PCD that has become available for healthcare 
research. The patients are drawn from the SystmOne GP database that covers over 28 million 
patients throughout the UK. The population covered by SystmOne has increased from 8.4% 
of GP practices in 2008 to 17.8% of practices in 2011. (Kontopantelis et al., 2013) As of 
2014 this database holds information for over 6 million patients.  The GP practices on the 
database are spread throughout the UK, representing 85% of UK local authorities, and 
deprivations analyses of the database indicate that the patients are from a representative mix 
of the UK population. (Kontopantelis et al., 2013; Reeves et al., 2014) The data accrued in 
the ResearchOne database include demographic information (including patient’s sex and year 
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of birth), clinical diagnoses, detailed prescription records, referrals to secondary care, and 
outcomes from hospital admission.  Important, historical clinical diagnoses that occurred 
before the introduction of the electronic medical record are also coded retrospectively. The 
data quality of each entry into ResearchOne is measured against specific targets, developed 
by comparisons with external statistics, to ensure that research standards are met.  
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Chapter 2 Aims and Objectives 
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Chapter 2: Aims and Objectives 
The aim of this thesis is to investigate the potential for the chemoprevention of IBD 
associated colorectal cancer. This will involve a systematic review of the literature to date 
and then, using primary care data, investigate whether there are associations between routine 
medication use and the development of IBD-CRC. 
2.1 Chemoprevention of IBD-CRC  
As already discussed, there are plausible mechanisms for the role of many 
medications in preventing IBD associated CRC. There have been several observational 
studies investigating the role of aspirin, non-aspirin non-steroidal medications and 
supplementation with folate. This evidence has not been synthesised, to date, and so the first 
two results chapters explore this potential by performing two systematic reviews and meta-
analyses to investigate any association with the use of these medications and supplement. 
2.2 Validation of the ResearchOne database 
In order to investigate the potential for chemoprevention, large databases are required 
as the outcome of IBD-CRC is relatively rare and takes a long time to develop. As such, 
prospective studies or cohorts are not feasible and for the same reasons, prospective 
randomised studies would be difficult or impossible. There are now several large cohorts 
available for biomedical research that draw from primary care records. In the UK, most 
people are registered with a GP, and nearly all GPs maintain electronic healthcare databases. 
This means that exploring these rich datasets can give estimates of population level disease 
aetiology and outcomes. They include large numbers of people and span several decades and 
so are a good resource for investigating rare events, and long-term disease outcomes.  
A novel primary care database is ResearchOne. A potential problem with using this 
resource is that it has not undergone data validation, which limits its utility. Before using this 
resource for chemoprevention work it is therefore important to perform a database validation 
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study. After the validation study the IBD and IBD-CRC cohorts within the ResearchOne 
database are described in detail with trends in incidence of IBD-CRC and description and 
analysis of aetiological factors associated with this disease.  
2.3 Chemoprevention of IBD-CRC using the ResearchOne database. 
The final results chapter involves several nested case-control studies to test the 
hypotheses that routinely prescribed drugs may be able to prevent IBD associated CRC. 
These include aspirin, NA-NSAIDs, statins, antiplatelets, 5-ASA, and immunomodulators. 
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Chapter 3:  Systematic review and meta-analysis of the role of aspirin and 
non-aspirin non-steroidal anti-inflammatory drugs in the 
chemoprevention of IBD associated CRC. 
In this chapter I will review the evidence for the potential role of aspirin and non-
aspirin non-steroidal anti-inflammatory agents (NA-NSAIDs) in the chemoprevention of IBD 
associated colorectal cancer. After discussing the available evidence, I will describe a meta-
analysis and pooled association size for the role of these drugs and, after discussing strengths 
and weaknesses of the evidence explore how this may affect future research and clinical 
practice. 
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3.1 Abstract 
3.1.1 Aim 
To determine whether aspirin or non-aspirin non-steroidal anti-inflammatory drugs 
(NA-NSAIDs) prevent colorectal cancer (CRC) in patients with inflammatory bowel disease 
(IBD). 
3.1.2 Methods 
I performed a systematic review and meta-analysis. I searched for articles reporting 
the risk of CRC in patients with IBD related to aspirin or NA-NSAID use. Pooled odds ratios 
(OR) and 95% confidence intervals were determined using a random-effects model. 
Publication bias was assessed using funnel plots and Egger’s test. Heterogeneity was assessed 
using Cochran’s Q and the I2 statistic. 
3.1.3 Results  
Eight studies involving 14,917 patients and 3 studies involving 1,282 patients 
provided data on the risk of CRC in patients with IBD taking NA-NSAIDs and aspirin 
respectively. The pooled OR of developing CRC after exposure to NA-NSAIDs in patients 
with IBD was 0.80 (95% CI, 0.39 to 1.21) and after exposure to aspirin it was 0.66 (95% CI 
0.06 to 1.39). There was significant heterogeneity (I2 > 50%) between the studies. There was 
no change in the effect estimates on subgroup analyses of the population studied and after 
adjustment and matching for known confounders.  
3.1.4 Conclusion 
There is a lack of high-quality evidence on this important clinical topic. From the 
available evidence NA-NSAID or aspirin use does not appear to be chemopreventative for 
CRC in patients with IBD.  
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3.2 Introduction 
As discussed, one of the most serious complications of inflammatory bowel disease 
(IBD) is the development of colorectal cancer (CRC). International society guidelines 
advocate regular surveillance colonoscopy examinations to identify malignant and pre-
malignant lesions. (Cairns et al., 2010) These are resource intensive and not without risk. As 
such primary prevention of CRC in these patients is an attractive alternative. Several 
treatment modalities have been proposed as potential chemopreventative agents and studied 
mainly via retrospective case-control and cohort studies. (Subramanian and Logan, 2011) 
These include 5-aminosalicylic acid preparations, (van Staa, 2005; Eaden, 2003; Terdiman, 
2011) ursodeoxycholic acid (in patients with concomitant PSC), (Low et al., 2010; Terhaar 
Sive Droste et al., 2006) thiopurine analogues, (van Schaik et al., 2012) aspirin and non-
aspirin non-steroidal anti-inflammatory drugs (NA-NSAIDs), and statins. (Poynter and 
Gruber, 2005)  
There are plausible biological mechanisms for how NA-NSAIDs, and aspirin, may 
prevent CRC development in patients with IBD. In epidemiological, laboratory and clinical 
studies aspirin has consistently been shown to reduce the incidence of several tumours, 
including ‘sporadic’ CRC. (Rothwell et al., 2010b; Burr et al., 2014) The exact anti-
neoplastic mechanism(s) of aspirin and NA-NSAIDs is not yet clear but several cell 
signalling pathways have been implicated as targets for COX-dependent and COX-
independent mechanisms of action. (Wang and Dubois, 2010; Schrör, 2011) Aspirin use also 
appears to prevent CRC metastasis, as well as the risk of primary CRC. (Rothwell et al., 
2012) 
There are currently conflicting data on the putative role of NA-NSAIDs and aspirin in 
the prevention of IBD-CRC. I therefore performed a systematic review and meta-analysis in 
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order to identify if there is evidence that aspirin and NA-NSAIDs have chemopreventative 
activity against CRC in patients with IBD. 
3.3 Materials and methods 
I followed a pre-specified and peer-reviewed protocol; the PRISMA statement, a 27 
item checklist deemed essential for reporting systematic reviews and meta-analyses of 
randomised controlled trials and observational studies. (Moher et al., 2009) 
3.3.1 Search strategy 
Multiple electronic databases were used including MEDLINE (1965 to July 2015), 
EMBASE (1974 to July 2015), ISI Web of Science (1945-July 2015) and the Cochrane 
Register of Controlled Trials. The MeSH search terms included were Inflammatory Bowel 
Disease AND CRC AND Aspirin OR NSAIDs. Free text terms and variations were used. No 
limits or language restrictions were applied.  A recursive search of the bibliographies of 
relevant review articles and of the included studies was performed. Articles were assessed by 
two independent reviewers (NB and VS) to assess eligibility for inclusion. Any 
disagreements were resolved by consensus decision. 
3.3.2 Study selection 
Studies were eligible for inclusion if they reported on the risk of developing CRC in 
patients with IBD on either NA-NSAIDs or aspirin compared to a control population. Studies 
published only in abstract form were not included. Two reviewers (NB and VS) 
independently screened titles and abstracts identified by the preliminary searches to identify 
potentially eligible studies. Both reviewers independently assessed the full text articles of 
potentially relevant studies for inclusion in the pooled analysis. Data from included studies 
were independently extracted by two investigators (NB and VS). Information was collected 
on the characteristics of each included study (population studied, country of origin, study 
design, definition of drug exposure) and drug use including NA-NSAIDs, aspirin and 
- 37 - 
development of CRC. Agreement between the reviewers was greater than 95% and 
differences between the datasets were resolved by consensus decision. 
3.3.3 Statistical Analysis 
The odds ratio (OR) with 95% confidence interval (CI) of developing CRC in patients 
with IBD on aspirin or NA-NSAIDs compared with controls was extracted from the study. 
When insufficient (no information on odds ratio or drug exposure) data had been published, I 
contacted the study authors. As randomisation and blinding is not possible in observational 
studies and baseline differences between the groups can confound the results, I used the 
authors’ ORs with adjustment for potential confounding factors wherever available. The 
pooled OR estimate was calculated from an inverse-variance-weighted average of the 
individual studies. (Yusuf et al.) A DerSimonian-Laird random effects model was used a 
priori. (DerSimonian and Laird, 1986) As a further sensitivity analysis a fixed effects model 
was used for comparison. Stata version 12 (StataCorp, College Station, Texas, USA), was 
used for all the data analysis.  
Cochran’s Q statistic was used to test heterogeneity among pooled estimates. 
(Cochran, 1954) Statistical heterogeneity was also measured by the I2 statistic, which 
quantifies the proportion of inconsistency in individual studies that cannot be explained by 
chance. (Higgins et al., 2003) Values of I2 equal to 25%, 50%, and 75% represent low, 
moderate, and high heterogeneity, respectively.  To test for publication bias, I used a test for 
asymmetry of the funnel plot, proposed by Egger et al. (Egger et al., 1997) This test detects 
funnel plot asymmetry by determining whether the intercept deviates significantly from zero 
in a regression of the normalised effect estimate (estimate divided by the standard error) 
against precision (reciprocal of the standard error of the estimate) weighted by the reciprocal 
of the variance of the estimate.  
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The quality of the primary studies assessing the risk of bias was evaluated using the 
Newcastle-Ottawa Scale for non-randomised studies (NOS). (Wells et al., 2000) Studies 
score for a maximum of 4 for selection, 2 for comparability and 3 for outcomes (cohort) or 
exposures (case-control). I regarded scores of 0-3 as low, 4-6 as medium and 7-9 as high 
methodological quality.  
Pre-planned subgroup analyses were conducted to assess the following factors on the 
trial outcome and on the heterogeneity of the analyses: a) matching or adjustment for 
confounders (any or none) and b) the population studied (population-based or other). 
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Figure 3 Flow diagram of studies included in the systematic review of 
aspirin and NA-NSAIDs in preventing IBD-CRC 
 
  
508 unique articles identified 
from database search
Excluded after screening title and 
abstract – 458
50 unique articles remaining Full text articles excluded - 42
Unique articles included in the 
analyses – 9
Data on NA-NSAIDs - 6
Data on aspirin – 1
Data on both medications - 2
1 article included from recursive 
search
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3.4 Results 
The searches retrieved nine potentially relevant articles, of which three (Eaden et al., 
2000; van Staa, 2005; Velayos et al., 2006) provided data on aspirin exposure and eight (van 
Staa, 2005; Velayos et al., 2006; Terdiman et al., 2007; Samadder et al., 2011; Bansal and 
Sonnenberg, 2013; Tang et al., 2010; Baars et al., 2011; Rubin et al., 2013) on NA-NSAID 
exposure and risk of CRC in patients with IBD. Figure 2 outlines the fate of the selected 
articles. The studies were either retrospective case-control, nested case-control or cohort 
studies by design and 5 (van Staa, 2005; Terdiman et al., 2007; Samadder et al., 2011; Bansal 
and Sonnenberg, 2013; Baars et al., 2011) included population-based analysis. Table 1 lists 
all the included studies and their characteristics.  Authors of relevant papers were contacted 
for missing data, but no extra information was obtained. The quality assessment of the studies 
using the Newcastle Ottawa scale is also detailed in Table 1. Only three studies (Velayos et 
al., 2006; Bansal and Sonnenberg, 2013; Samadder et al., 2011) provided multivariate 
analysis of data for risk of developing CRC in IBD patients exposed to aspirin or NA-
NSAIDs.  
3.4.1 Cumulative risk of developing colorectal cancer in IBD patients 
exposed to NA-NSAIDs 
Eight studies, including 14, 917 patients with IBD provided data on the risk of 
developing CRC after exposure to NA-NSAIDs. Using a random effects model, the pooled 
adjusted OR of developing CRC after exposure to NA-NSAIDs in patients with IBD was 
0.80 (95% CI 0.39 to 1.21) (Figure 2). The heterogeneity between the studies was high 
(Cochran’s Q = 38.15, p=0.00 and I2=81.6%).  
- 41 - 
Table 1 Characteristics of the eligible studies in the meta-analysis of aspirin and NA-NSAIDs in the 
chemoprevention of IBD-CRC 
Author Design Population 
Definition of 
IBD Drug exposure Exclusion criteria 
No. of 
patients OR (95% CI) 
Adjustment/matching
* 
NOS Quality 
assessment 
 
Bansal, 
1996(Bans
al and 
Sonnenber
g, 2013) 
 
Case-
control 
 
US veterans’ 
affairs 
Clinical 
database 
NSAID 
associated 
Diagnosis 
Not specified 11446 0.84 (0.65-1.09) 
adjusted for age, sex 
& ethnicity 
6 
Eaden, 
2000(Eade
n et al., 
2000) 
Case-
control 
UK hospital  
Clinical, 
pathological and 
radiological 
records. 
Prescribed 5-10 
years before 
diagnosis. 
Colorectal 
surgery, IBD 
diagnosed at time 
of cancer 
diagnosis 
206 
0.80 (0.21-2.98) 
Aspirin 
non-adjusted 4 
Van Staa, 
2005(van 
Staa, 2005) 
Nested 
case-control 
UK general 
practice 
Clinical records 
Prescribed in 
the 6 months 
prior to 
diagnosis 
Colorectal 
surgery, previous 
history of CRC 
700 
 
1.52 (0.7-3.25) 
(Aspirin) 
0.80 (0.38-1.66) 
(NA-NSAID’s) 
 
non-adjusted 5 
Velayos, 
2006(Velay
os et al., 
2006) 
Case-
control 
US hospital 
Clinical, 
pathological and 
endoscopic 
records 
2 records of use 
in notes 
Previous CRC, 
IBD diagnosed at 
same time as 
CRC, incomplete 
data 
376 
0.3 (0.1-0.8) 
(Aspirin) 
0.1 (0.03-0.5) 
(NA-NSAID) 
 
matched on gender, 
duration of disease 
and extent of disease 
8 
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Terdiman, 
2007(Terdi
man et al., 
2007) 
Case-
control 
US insurance 
claims 
Clinical records 
Prescribed in 
the year before 
diagnosis 
Colorectal 
surgery 
1536 0.97 (0.74-1.28) non-adjusted 5 
Tang, 
2010(Tang 
et al., 
2010) 
Retrospecti
ve cohort 
US hospital 
Clinical 
database 
Ever used 
No colonic 
involvement of 
IBD 
 
48 0.29 (0.03-2.75) non-adjusted 5 
Sammader, 
2011(Sama
dder et al., 
2011) 
Case-
control 
N. Israel 
community  
Patient 
questionnaires 
Weekly for >3 
years 
Previous history 
of CRC 
 
60 0.49 (0.07-3.32) 
matched for age, 
gender & ethnicity 
6 
Baars, 
2011(Baars 
et al., 
2011) 
Case-
control 
Netherlands 
nationwide 
pathology 
Pathology 
reports 
Ever used 
IBD diagnosed at 
the same time as 
CRC 
 
551 1.96 (0.72 -5.36) non-adjusted 6 
Rubin, 
2013(Rubi
n et al., 
2013) 
Case-
control 
US hospital 
Pathology 
reports 
Not specified. 
Incomplete 
records 
200 1.84 (0.75-2.5) non-adjusted 5 
# OR for CRC chemoprotective effect of non-aspirin non-steroidal (NA-NSAID) use in patients in IBD unless otherwise stated. 
NOS – Newcastle-Ottawa Score. Note - for cohort studies was used only for the Tang et al study. The scale for case-control studies was used for the other studies.  
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Table 2  Subgroup analyses for studies reporting on risk of CRC in 
patients with IBD taking NA-NSAIDs 
   
 
Number 
of studies 
Pooled OR (95% CI) 
Matched y/n    
Matched/adjusted 3 0.47 (0.18 to 1.13) 
None 5 1.04 (0.65 to 1.43) 
Study location   
Hospital 6 0.92 (0.78 to 2.62) 
Population 2 0.88 (0.72 to 1.04) 
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3.4.2 Sensitivity analysis and publication bias 
Pre-planned subgroup analyses showed that there was no difference in the overall 
effect estimate when comparing the population studied or whether adjustment or matching for 
confounders was performed (Table 2).  There was no heterogeneity among population-based 
studies (Cochran’s Q=2.39, p = 0.79 and I2=0%) but high heterogeneity between hospital-
based studies (Cochran’s Q=14.17, p < 0.05 and I2=92%)).  There was some funnel plot 
asymmetry compatible with publication bias (Figure 4). However, Egger’s regression 
asymmetry test was non-significant (p = 0.56). The regression asymmetry test is probably 
underpowered as there are only 8 studies included in this meta-analysis. (Sterne et al., 2011)  
3.4.3 Cumulative risk of developing CRC in IBD patients exposed to 
aspirin 
Three studies, including 1,282 patients with IBD, provided data on risks of 
developing CRC after exposure to aspirin. The pooled adjusted OR of developing CRC after 
exposure to aspirin in patients with IBD was 0.66 (95% CI 0.06 to 1.39) (Figure 3). A 
random effects model was chosen a priori. The heterogeneity between the studies was high 
(Cochran’s Q = 0.166 and I2 = 44.4%). A fixed effects model was performed as a sensitivity 
test which changed the pooled adjusted OR to 0.41 (95% CI 0.08 to 0.74). I did not attempt to 
perform an analysis of publication bias or subgroup analyses as there were only three studies 
included in the final analysis. 
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Figure 4 Forest Plot of ORs and 95% CI for effect of NA-NSAIDs or 
aspirin on CRC development in patients with Inflammatory Bowel 
Disease. Random effects model 
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Figure 5 Funnel Plot for publication bias for studies looking at the 
odds ratio of developing colorectal cancer in patients with 
inflammatory bowel disease on non-aspirin non-steroids anti-
inflammatory drugs (NA-NSAIDs). 
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3.5 Discussion 
I present the first systematic review and meta-analysis of the effects of NA-NSAIDs 
and aspirin for CRC chemoprevention in patients with IBD to my knowledge. It is important 
to synthesise the available literature on this subject as CRC remains an important 
complication of IBD and NA-NSAIDs including aspirin have been consistently shown to 
have a protective effect in sporadic colorectal cancer. (Chubak et al., 2015; Friis et al., 2015) 
Nine retrospective studies were included that met the inclusion criteria, but unfortunately 
there have been no prospective randomised trials. There were only three studies that reported 
on aspirin use in patients with IBD associated cancer.  I found no significant potential 
protective effect for NA-NSAIDs or aspirin against the development of CRC in IBD patients. 
There are several limitations to this meta-analysis. All the included studies are 
retrospective and are therefore subject to inherent biases and confounding. Publication bias is 
another possible limitation as negative studies are less likely to be published and therefore not 
included in the analyses. However, I have attempted to reduce the possibility of publication 
bias by conducting an exhaustive search of the literature and did not limit inclusion of studies 
based on language.  Most of the studies included in my analysis reported NA-NSAID and 
aspirin use as a secondary outcome measure and results from a multivariate analysis was 
provided only by three studies. (Velayos et al., 2006; Samadder et al., 2011; Bansal and 
Sonnenberg, 2013) The study with the most robust methodology from Velayos et al. 
(Velayos et al., 2006) reported a significant chemopreventative role for both NA-NSAIDs 
and aspirin. There were differences in the studies related to the definition of drug exposure 
and as these studies were all retrospective it was not possible to check compliance with the 
medication. A further limitation with studies of this type is confounding by indication. 
Aspirin and NA-NSAID use could be associated with another factor, such as another medical 
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condition, that is associated with colorectal cancer. It is not possible to adjust or correct for 
all such factors so this always must be borne in mind when interpreting such studies. 
The dose and duration of drug exposure was not consistently recorded. An important 
consideration of chemoprevention against colorectal cancer is the duration of exposure to the 
medication. In the evidence for aspirin protecting against sporadic CRC a duration of >5 
years conferred a 34% reduction in CRC risk. (Chan et al., 2012) The only study included 
here which took this into consideration was Eaden et al. (Eaden et al., 2000) where a 
prescription in the preceding 5-10 years before diagnosis was required for inclusion as 
positive exposure (Table 1).  The dose of aspirin used was not stated in most of the studies, 
but it is likely to have been low dose as used in routine clinical practice in patients with 
cardiovascular risk factors, 75mg in the United Kingdom and 81mg in the United States. It is 
possible that a higher dose may be needed for chemoprevention of colitis-associated CRC. 
For example, a recent trial in patients with Lynch syndrome, a hereditary condition associated 
with high risk of CRC, demonstrated that high dose (600 mg daily) aspirin conferred 
protection against CRC. (Burn J. Mathers J. Bishop, 2012) Little information was provided 
about the timing and duration of exposure to aspirin and NA-NSAID’s in any of the included 
studies. Aspirin and NA-NSAIDs may be unable to prevent the progression from dysplasia to 
cancer and could therefore be chemopreventative only in those with exposure to the drug 
from soon after onset of IBD and those with longer duration of exposure to the medication. 
Unfortunately, none of the studies included in this meta-analysis provided data on the timing 
of exposure to NA-NSAID or aspirin and the duration of IBD, to determine if early or long-
term exposure was chemopreventative. The main outcome of interest was the development of 
CRC and not dysplasia which could support the argument that in some of the patients, CRC 
may have developed in those exposed to aspirin or NA-NSAIDs only after they had already 
developed colorectal neoplasia.  
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Adverse effects of NSAIDs on the gastrointestinal tract need to be considered in 
future studies as there is a potential increased incidence of disease flares with the use of 
NSAIDs, including aspirin.(Singh, Graff and Bernstein, 2009) This issue is still under debate 
as NSAIDs are often used for treatment of other conditions such as abdominal or 
musculoskeletal pain which are associated with flares of IBD. The NSAIDs therefore may be 
used after the flare has started to develop rather than being the cause of the IBD flare.   
CRC remains an important complication of IBD. Current methods to reduce CRC in 
IBD are the use of colonoscopic surveillance or by prophylactic proctocolectomy. British 
Society of Gastroenterology guidelines advocate screening and surveillance colonoscopy 
which can result in annual tests for high risk patients. (Cairns et al., 2010) Chemoprevention 
is therefore an attractive proposition for these patients. NA-NSAIDs and aspirin remain 
biologically plausible targets for chemoprevention in IBD. As I have shown, the clinical 
evidence is limited. The available data are hampered by the fact that most of the studies 
include small numbers of patients and do not include adequate information on medication 
dose and duration. Potential chemoprevention agents are likely to take several years to 
display a protective effect as in the sporadic CRC population and this should be borne in 
mind in future studies.  Prospective randomised chemoprevention trials are unlikely to be 
performed as the sample size required would be too large and therefore well-conducted 
epidemiological studies using prospectively recorded databases are needed to clarify the true 
effect of aspirin and/or NA-NSAIDs on the risk of CRC in patients with IBD. 
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Chapter 4: Systematic review and meta-analysis of the role of folate in the 
chemoprevention of IBD associated CRC 
In this chapter I will review the evidence for the potential role of folate 
supplementation in the chemoprevention of IBD associated colorectal cancer. After 
discussing the available evidence, I will describe the meta-analysis and pooled association 
size for folate and, after discussing strengths and weaknesses of the evidence and describe the 
impact of these findings.   
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4.1 Abstract 
4.1.1 Aims 
To evaluate the role of folic acid supplementation in colorectal cancer (CRC) 
chemoprevention in patients with inflammatory bowel disease (IBD). 
4.1.2 Background 
CRC is a serious complication of IBD. Folic acid supplementation has been shown to 
be chemopreventative in sporadic CRC. Patients with IBD are at risk of folate deficiency 
though intestinal malabsorption and competitive inhibition by concurrent sulfasalazine use.  
To date there have been several studies reporting on folic acid supplementation in patients 
with IBD and CRC.  
4.1.3 Study 
I searched electronic databases for studies reporting folic acid use and CRC incidence 
in patients with IBD. I produced a pooled Hazard Ratio (HR) with 95% confidence intervals 
(CI) using a random effects model. Pre-planned subgroup analyses were performed to explore 
for any potential sources of heterogeneity. 
4.1.4 Results 
Ten studies reporting on 4,517 patients were included. I found an overall protective 
effect for folic acid supplementation on the development of CRC, pooled HR 0.58 (CI 95% 
0.37 to 0.80). There was low to moderate heterogeneity amongst studies, I2 = 29.7%. 
Subgroup analyses suggested that folic acid use was protective in hospital-based studies, 
studies from North America and those that were performed before folate fortification of foods 
in 1998.  
4.1.5 Conclusion 
CRC remains an important complication of IBD. Chemoprevention is an attractive 
strategy and folic acid as a cheap, safe and well tolerated supplement may have a role. 
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Focussed prospective studies are required in high risk groups to explore this association 
further and try and define whether there is a protective causal relationship between folate and 
IBD-CRC.  
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4.2 Introduction 
As already discussed, chemoprevention of IBD-CRC is an attractive target as medical 
and surgical treatment of neoplasia is associated with substantial morbidity and mortality.  
Folate (vitamin B9) is the generic term for a group of compounds, including folic acid 
as a supplement, that are essential for numerous bodily functions. (Scaglione and Panzavolta, 
2014) Folate deficiency in humans causes neural tube defects in embryos and megaloblastic 
anaemia in adults. Humans cannot synthesise folate, so it is obtained from foods such as leafy 
green vegetables, folic acid in supplements or food fortification, mandatory in the United 
States and Canada since 1998. Folate has a role in DNA methylation and purine and 
thymidine synthesis for DNA and RNA (Choi and Mason, 2000) and has been implicated in 
carcinogenesis through permitting increased DNA damage and altering the expression of 
critical tumour suppressor and proto-oncogenes. (Kim, 1999) This is supported by 
experimental studies in rats where folate deficiency has been shown to induce CRC and folate 
supplementation inhibits it. (Cravo et al., 1992; Kim et al., 1996) There is evidence for a 
“dual role” of folate in carcinogenesis whereby folate may prevent early cancers but cause 
harm if these lesions have formed. (Kim, 2007; Ulrich and Potter, 2006) These studies, in 
mice with CRC, showed that high levels of folate promoted carcinogenesis once microscopic, 
neoplastic foci had developed. (Song et al., 2000a, 2000b)  
Epidemiological studies have shown that reduced folate levels are associated with the 
development of several solid tumours including cervical, breast, pancreas, lung and CRC. 
(Freudenheim et al., 1991; Wien et al., 2012) Some of the most compelling evidence is for 
CRC, a recent meta-analysis of 27 papers showed a relative risk estimate reduction of 0.85 
(95% CI 0.74 to 0.99) when comparing low vs high folic acid supplementation. (Kennedy et 
al., 2011)  Individuals with IBD are at increased risk of folate deficiency through inadequate 
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nutritional intake, excessive intestinal loss and reduced absorption due to competitive 
inhibition by sulfasalazine use. (Potack and Itzkowitz, 2008; Swinson et al., 1981)  
4.2.1 Aims 
There have been several studies reporting the effect of folic acid supplementation on 
the chemoprevention of CRC in those with IBD but the results to date remain inconclusive. 
The aim of this study was to perform a comprehensive review and meta-analysis to see if 
there is evidence for the use of folic acid in chemoprevention against CRC in patients with 
IBD. 
4.3 Materials and Methods  
I followed pre-specified and peer-reviewed MOOSE (Meta-analysis of Observational 
Studies in Epidemiology) guidelines for reporting systematic reviews and meta-analyses of 
observational studies. (Stroup, 2000) 
4.3.1 Search strategy 
Separate electronic database searches were performed on MEDLINE (1946 to 
September 2015) and EMBASE (1947 to September 2015). Further searches were conducted 
on The Cochrane Library for systematic reviews and assessment evaluations and the National 
Health Service (UK) Economic Evaluation Database to September 2015. I also searched ISI 
Web of Science to capture conference abstracts and proceedings. The search terms used were 
inflammatory bowel diseases, Crohn’s disease, ulcerative colitis, colorectal neoplasms and 
folic acid. Medical subject heading (MeSH), free text terms and variations were used.  No 
limits or language restrictions were applied.  I performed a recursive search of the literature 
by reviewing the bibliographies of the relevant articles identified from the search strategy. 
Articles were assessed by two independent reviewers (NB and VS) to assess eligibility for 
inclusion. Any disagreements were resolved by consensus decision. 
4.3.2 Study selection 
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Studies were eligible for inclusion if they reported on the risk of developing CRC in 
patients with IBD on folic acid supplementation compared to a control population. Two 
reviewers (NB and VS) independently screened titles and abstracts identified by the 
preliminary searches to identify potentially eligible studies. Both reviewers independently 
assessed the full text articles of studies for inclusion in the pooled analysis. Data extraction 
was performed by two investigators (NB and VS) and included the characteristics of the 
study (population studied, country of origin, study design, definition of drug exposure) and 
medication use including folic acid supplementation and development of CRC. Agreement 
between the reviewers was greater than 95% and differences between the datasets were 
resolved by discussion. 
4.3.3 Statistical Analysis 
The effect size with 95% confidence intervals (CI) of developing CRC in IBD 
patients with and without folic acid supplementation was extracted from each study. Where 
possible I extracted HR with 95% confidence intervals. If the desired data was not reported in 
the study I converted the effect size estimates to a consistent HR format using methods 
outlined by Parmar et al, 1998 (Parmar, Torri and Stewart, 1998) using the Microsoft Excel 
spreadsheet produced by Tierney et al, 2007. (Tierney et al., 2007) 
As randomisation and blinding is not possible in observational studies and baseline 
differences between the groups can confound the results, I used the authors’ HR with 
adjustment or matching for potential confounding factors wherever available. A 
DerSimonian-Laird (DerSimonian and Laird, 1986) random effects model was used a priori 
for pooling the HRs. I subsequently performed a fixed effects model as a sensitivity test. I 
also used the Cochran’s Q statistic to test heterogeneity among pooled estimates. (Cochran, 
1954) Statistical heterogeneity was further measured by the I2 statistic, which quantifies the 
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proportion of inconsistency in individual studies that cannot be explained by chance. 
(Higgins et al., 2003)  
- 58 - 
Figure 6 Flow chart of included studies in the systematic review and 
meta-analysis of the role of folate medications in the chemoprevention 
of IBD-CRC 
 
  
648 unique articles identified 
from database search
450 articles excluded after reviewing title 
and abstract
198 unique articles remaining
Papers excluded as: 
Review article - 19
No relevant information - 168
Primary sclerosing cholangitis patients 
only - 1
Unique articles included in 
the analyses - 10
Cohort studies - 4
Case-control studies - 6
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Values of I2 equal to 25%, 50%, and 75% represent low, moderate, and high 
heterogeneity, respectively. As a further sensitivity test, I excluded studies with significant 
heterogeneity to see if there was a change in the overall observed effect.  To test for 
publication bias, I used a test for asymmetry of the funnel plot proposed by Egger et al. 
(Egger et al., 1997) This test detects funnel plot asymmetry by determining whether the 
intercept deviates significantly from zero in a regression of the normalised effect estimate 
(estimate divided by the standard error) against precision (reciprocal of the standard error of 
the estimate) weighted by the reciprocal of the variance of the estimate.  
The quality of the primary studies assessing the risk of bias was evaluated using the 
Newcastle-Ottawa Scale for non-randomised studies (NOS) (Wells et al., 2000). Studies 
score a maximum of 4 for selection, 2 for comparability and 3 for outcomes (cohort) or 
exposures (case-control). I regarded scores of 0 to 3 as low, 4 to 6 as medium and 7 to 9 as 
high methodological quality.  
4.3.4 Subgroup analyses 
Pre-planned subgroup analyses were performed to explore potential sources of 
heterogeneity by assessing the influence of several factors on the overall effect estimate. 
These were 1) outcome studied (CRC or any dysplasia), 2) whether the study reported 
outcomes after matching or adjustment (yes vs no), 3) the population studied (hospital based 
or population-based), 4) whether the study was performed before introduction of folate 
fortification (pre or post 1998), 5) NOS study quality (≥7 vs <7) and 6) geographic location 
of study (North America vs Europe). All analyses were conducted using Stata statistical 
software (version 12, Stata Corp, College Station, TX). 
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Table 3 Characteristics of the studies included in the systematic review and meta-analysis of the role of folate medication in 
the chemoprevention of IBD-CRC 
Author, 
year 
Design Population IBD 
Duration 
of IBD 
Neoplasia Folic acid exposure 
Study size 
(cases/controls) 
HR (95% CI) 
AD 
 
HR (95% CI) 
CRC 
Matching 
criteria 
Newcastle-
Ottawa Score 
for quality 
Lashner, 
1989(Lash
ner et al., 
1989) 
Cohort US hospital UC† > 7yrs AD 
0.4mg or 1mg, ever 
used 
88 (29/59) 
0.41 (0.19-
0.88)  
None 7 
Lashner, 
1997(Lash
ner et al., 
1997) 
Cohort US hospital UC† > 8yrs 
CRC or 
AD 
0.4mg or 1mg, > 6 
months.  
97 (29/68) 
0.59 (0.28-
1.24) 
0.44 (0.66-
1.24) 
None 7 
Rutter, 
2004(Rutte
r et al., 
2004a) 
Case-
control 
UK hospital UC   > 8yrs 
CRC or 
AD 
"any" 42 (14/28) 
0.74 (0.13-
4.16) 
0.54 (0.05-
6.28) 
Gender, 
duration of 
disease, extent 
of disease 
7 
Siegel, 
2006(Sieg
el and 
Sands, 
2006) 
Case-
control 
US hospital 
CC 
All 
patients 
CRC 
"any" 
54 (27/27) 
1.00 (0.04-
2.48)  
Gender, 
duration of 
disease  
7 
Velayos, 
2006(Vela
yos et al., 
2006) 
Case-
control 
US hospital UC "chronic" CRC "any" 376 (188/188) 
0.79 (0.48-
1.32)  
Gender, 
duration of 
disease, extent 
of disease 
6 
Gupta, 
2007(Gupt
a et al., 
2007) 
Cohort US hospital   UC > 7yrs 
CRC* or 
AD 
"any" ** 
0.90 (0.50-
1.60) 
1.30 (0.40-
3.70) 
None 7 
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Tang, 
2010(Tang 
et al., 
2010) 
Case-
control 
US hospital 
UC or 
CD 
All 
patients 
CRC 1mg, ever used.  48 (18/30) 
0.23 (0.09-
0.58)  
None 7 
Baars, 
2011(Baar
s et al., 
2011) 
Case-
control 
Netherlands 
nationwide 
pathology 
database 
UC or 
CD 
All 
patients 
CRC "any"  551 (159/392) 
0.83 (0.05-
1.38)  
None 6 
Van 
Schaik, 
2012(van 
Schaik et 
al., 2012) 
Cohort 
Netherlands 
nationwide 
insurance 
database 
UC or 
CD 
> 6 months CRC* "any"  2578 (28/2550) 
2.11 (0.45-
9.94)  
None 9 
Rubin, 
2013(Rubi
n et al., 
2013) 
Case-
control 
US hospital UC 
All 
patients 
AD "any"  199 (59/140) 
0.77 (0.46-
1.28)  
Age, duration of 
disease, extent 
of disease 
7 
       
 
 
    
 
Abbreviations used:  
UC - ulcerative colitis, CD - Crohn's disease, CC - Crohn's colitis, AD - 
any dysplasia, CRC - colorectal cancer 
 
 
 
  
 
 
  
HR - hazard ratio.  
 
    
 
† 
pancolitis 
      
 
 
 
  
 
 
* advanced neoplasia 
 
 
 
    
 
** some patients excluded as missing data, unknown number 
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4.4 Results 
The search strategy and results are shown in figure 5. Ten studies were included in the 
meta-analysis which reported on 638 cases of IBD associated CRC. (Lashner et al., 1989, 
1997; Rutter et al., 2004a; Velayos et al., 2006; Siegel and Sands, 2006; Gupta et al., 2007; 
Tang et al., 2010; Baars et al., 2011; van Schaik et al., 2012; Rubin et al., 2013) Of note, the 
study by Shetty et al. (Shetty et al., 1999) was not included as it included only patients with 
co-existing primary sclerosing cholangitis. The individual study details are shown in table 3. 
There was variation in study design (case-control or cohort), sample size, location, population 
studied and the reporting on dose and duration of folic acid use. Folic acid was the primary 
measure in 2 of the studies, (Lashner et al., 1989, 1997) the remainder reporting it as a 
secondary outcome measure. The overall study quality was high with 8 of the 10 studies 
having a NOS score of ≥7 (table 1).  Pooling of the effect estimates from the studies (Figure 
6) resulted in a HR of 0.58 (CI 95% 0.37 to 0.80). This result was maintained when 
performing a fixed effect model analysis, pooled HR 0.51 (CI 95% 0.36 to 0.66).  I 
performed a series of planned subgroup analyses (Table 4).   Folic acid use was protective in 
hospital rather than population-based studies, studies conducted in the United States of 
America, high quality studies, unmatched studies and studies conducted before the 
introduction of food fortification in 1998. 
To test for publication bias, I constructed a funnel plot (Figure 7). There was some 
asymmetry in the funnel plot suggesting that there may be some publication bias. Egger’s 
regression asymmetry test however was not significant (p = 0.83). Publication bias does 
remain a possibility as there were only 10 studies in the analyses and in this scenario the 
ability of Egger’s test to detect a potential bias is limited.  
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Figure 7 Hazard ratios (HR) and 95% confidence intervals for folic 
acid as a chemopreventative agent against the development of CRC in 
IBD. Random effects model. 
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Figure 8 Funnel plot of studies evaluating folic acid in the 
chemoprevention of CRC in patients with IBD. 
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Table 4 Subgroup analyses in the chemoprevention of IBD-CRC by 
folate medications 
   
Heterogeneity 
 
Number 
of studies 
Pooled HR (95% CI) 
Cochran's 
Q 
p-value I2 (%) 
Dysplasia 
     
CRC 5 0.62 (0.41-0.83) 2.96 0.56  
Any dysplasia 8 0.63 (0.31-0.94) 10.88 0.14 35.7 
Matched y/n  
 
    
Matched/adjusted 4 0.80 (0.52-1.08) 0.17 0.98  
None 6 0.54 (0.28-0.79) 9.38 0.10 46.7 
Study location 
 
    
Hospital 8 0.58 (0.37-0.79) 11.53 0.12 39.3 
Population 2 0.84 (0.40-1.28) 0.28 0.60  
Folate fortification 
 
    
Before 2 0.47 (0.20-0.75) 0.36 0.55  
After 5 0.66 (0.32-1.00) 11.05 0.03 63.8 
Study quality 
 
    
NOS ≥7 8 0.47 (0.26-0.67) 7.37 0.29 18.6 
NOS <7 2 0.83 (0.56-1.10) 0.10 0.95  
Geographic location 
 
    
US 7 0.58 (0.36-0.81) 11.48 0.08 47.7 
Europe 3 0.84 (0.41-1.26) 0.29 0.87  
NOS – Newcastle-Ottowa scale 
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4.5 Discussion 
I have shown that there is a significant negative association with folic acid 
supplementation and CRC incidence in patients with IBD. There was however marked 
variation in study design, so more work is needed to substantiate this association. The 
potential effect of folic acid has been more rigorously investigated for sporadic colorectal 
cancer (Kennedy et al., 2011) but there is a paucity of data in the IBD population who are not 
only at greater risk of CRC but also folate deficiency. This review builds on the initial work 
by Lashner et al. in 1989 (Lashner et al., 1989) and 1997 (Lashner et al., 1997) where non-
significant reductions in CRC lead to some physicians advocating the use of folic acid as a 
chemopreventative agent in the UC population. (Potack and Itzkowitz, 2008) 
There are several important limitations to this analysis. All of the studies are 
retrospective and are subject to inherent biases associated with case-control and cohort 
studies. (Mann, 2003) Importantly they are unable to control for all possible confounding 
factors and indeed some of the studies included here report unadjusted and unmatched results. 
Important confounders that should be considered in future studies are family history of 
sporadic CRC, frequency of consultation and colonoscopy, smoking, obesity, other 
medications or supplements known to affect sporadic colorectal cancer risk. IBD-associated 
factors of extent, duration and severity of disease should also be included.  It is important to 
stress that the results seen are association only and a causal effect of folate on preventing 
IBD-CRC cannot be assumed based on these results. There may be other confounding factors 
associated with folic acid use that have not been accounted for in the retrospective studies 
included. One such associated factor is that patients taking health supplements are known to 
cluster healthy behaviours which may reduce their CRC risk. (McNaughton et al., 2005). It 
may be an associated healthy behaviour, that is responsible for the reduced incidence of CRC 
rather than the folate supplementation. A further consideration is the indication for folate 
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prescription, and whether it is this indication, rather than the prescription that has an 
influence on CRC risk. Folate medication is prescribed for several conditions that may be 
associated with IBD-CRC risk. Folic acid is co-prescribed with the folate antagonist 
methotrexate, which is prescribed in chronic inflammatory conditions, to prevent deficiency. 
As discussed, chronic colonic inflammation is associated with IBD-CRC risk (Rutter et al., 
2004a) so the methotrexate co-prescribed with the folic acid may be responsible for the 
negative association. I was not able to explore this in the studies involved in the meta-
analysis. However, methotrexate is not commonly used in colonic IBD due to lack of efficacy 
(Wang et al., 2015) so I would not expect this to account for all of the association seen. Folic 
acid supplementation is given to young women hoping to conceive. Young age and female 
sex are associated with a reduction in CRC (Johnson et al., 2013b) so this may contribute to 
some of the negative association seen. Chronic alcoholism is one of the principal reasons for 
folate deficiency, (Allen, 2008) but a meta-analyses of risk factors for sporadic CRC did not 
show any association between alcohol intake and CRC. (Johnson et al., 2013a) Alcohol use is 
associated with smoking, and smoking is positively associated with CRC. This interaction 
may mean that folate prescription is associated with an increased CRC population risk due to 
the positive association with alcohol and smoking. Overall, these potential confounding 
factors need to be considered, and there are positive and negative associations with CRC risk 
and folate supplementation. This highlights the need for further confirmatory studies, and 
ideally prospective controlled trials, that although difficult and expensive to conduct can 
provide more definitive evidence of any chemopreventative role of folate. There was 
significant variation in design of the studies included in our analyses. To account for some of 
the important differences I performed a series of subgroup analyses (Table 4). Due to the low 
numbers of studies in some of the subgroup arms these results should be interpreted with 
caution. I found that hospital-based patients had potential protection from folic acid 
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supplementation, which would be expected as these patients are likely to have more 
significant disease burden from their IBD with increased inflammation and subsequent 
malignant potential. There was also a difference in association when comparing studies 
performed before and after folate fortification in the United States of America in 1998. When 
comparing studies before and after the introduction of folate the effect estimate changed from 
0.47 (95% CI 0.2 to 0.75) to 0.66 (95% CI 0.32 to 1.00). Although only a slight change in the 
effect estimate there is a borderline loss of statistical significance and the effect estimate 
change supports our biological hypothesis as the control populations after 1998 are likely to 
be receiving greater amounts of folate through food fortification. The protective effect was 
maintained when analysing high quality studies, NOS >7. This would support the effect being 
a true association as the better-quality studies would be expected to have less bias and 
confounding through increased methodological rigor.  
Meta-analyses are subject to publication and reporting bias and it is possible that 
some of the 24 studies not included (Figure 5) did not report on folic acid use in their 
analyses as it showed no association. There may also be some dedicated studies which 
showed negative results that have not been published. To reduce the potential for any 
publication bias I did an exhaustive literature search which included the “grey literature” and 
did not have any language restrictions. To check for publication bias, I produced a funnel plot 
along with Egger’s regression asymmetry test. The funnel plot had some asymmetry; 
however, Egger’s test was non-significant. While this does not exclude the possibility of 
publication bias, the extensive search of the literature performed reduces the risk of relevant 
published articles being excluded in this analysis. Another problem when analysing non-
prescription supplements such as folate is not being able to account for “over the counter” 
use. This use would, however, lead us to underestimate the true effect as patients taking these 
supplements would most likely be counted as controls in the studies included. Unfortunately, 
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most of the studies did not report on the dose of folate or duration of use. As such I was 
unable to calculate any dose or time response gradients which would strengthen an 
aetiological hypothesis. As with sporadic CRC, higher doses of folate may lead to a greater 
chemopreventative effect. (Kennedy et al., 2011) Future studies should attempt to quantify 
folate exposure to aid these analyses.  
CRC remains an important and serious complication of both UC and colonic CD. 
There are plausible mechanisms for the chemopreventative effects of folate through its 
essential role in DNA replication and cell division. A deficiency in tissues with rapidly 
dividing cells, such as colonic epithelium, can result in ineffective DNA synthesis and repair, 
altered expression of critical tumour suppressor genes and proto-oncogenes and subsequent 
carcinogenesis. (Choi and Mason, 2000; Kim, 2004, 1999) 
Chemoprevention remains an attractive option for patients with IBD to prevent 
dysplasia, reduce the burden of surveillance colonoscopy and reduce the need for 
proctocolectomy in patients with UC. The ideal chemopreventative agent would be safe, well 
tolerated, inexpensive and have a role in suppressing inflammation and malignant 
transformation (Lakatos and Lakatos, 2008) and folic acid fits these criteria.  Any further 
reduction to the risk of CRC in IBD is welcomed and folic acid supplementation, as a safe 
intervention, may be an attractive option if further focused population-based studies on this 
topic confirm the findings of this meta-analysis.  
- 70  
Chapter 5 Validation study of the 
ResearchOne primary care database for use 
in IBD research 
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Chapter 5: Validation of the ResearchOne Primary care database for use 
in IBD research. 
In this chapter I will describe a validation study of the ResearchOne dataset 
undertaken at Leeds Teaching Hospitals NHS Trust.  
5.1 Abstract for the validation study 
5.1.1 Background 
Electronic health records from primary care databases are an important resource for 
biomedical research. They allow the analysis of large cohorts, long-term trends and 
investigation into rare outcomes. The SystmOne primary care database is one of the largest in 
the United Kingdom (UK) and includes clinical records from ~ 2,700 UK general practices. 
ResearchOne is an ethically approved dataset that comprises a subset of ~6 million individual 
clinical records from SystmOne. 
Despite the growing use of electronic datasets there are uncertainties around data 
quality and completeness. Data are sparse on the validity of chronic disease diagnoses within 
primary care databases and the SystmOne database has not been externally validated to my 
knowledge before this project.  
5.1.2 Methods 
I recruited individuals from the IBD out-patient clinic at Leeds Teaching Hospitals 
NHS Trust, UK. The latest IBD diagnosis was recorded, namely; UC, CD or IBD-
unclassified, the date of first diagnosis, first GI resectional surgery after an IBD diagnosis and 
the type of surgery performed. The hospital records were compared with primary care 
recorded entries, taking the hospital clinical and histopathological records as the reference 
standard.  In the primary analyses the accuracy of diagnoses recorded on the SystmOne 
primary care database was investigated, as a secondary outcome I included other primary care 
databases and reported pooled results. I calculated the proportion of individuals with accurate 
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clinical data on the primary care databases, and those with a recorded date accurate to within 
12 months.  
5.1.3 Results  
147 adults with a hospital diagnosis of IBD were included. One hundred patients had 
primary care records held on the SystmOne database. The only other PCD included was 
EMIS, with the remaining 47 patients. For SystmOne: IBD diagnoses were recorded in 98% 
of patients, 93% had the correct IBD subtype, and 85% had the first date of diagnosis 
accurate to within 12 months. GI surgical resections were recorded in 91% of cases, recorded 
as the correct procedure type in 81% of cases and the procedure date was correct to within 12 
months in 95% of cases. There was no difference when comparing results between SystmOne 
and EMIS 
5.1.4 Conclusions 
I have shown that IBD and surgical diagnosis codes, present in a hospital medical 
record, are recorded in over 90% of those with IBD in the primary care database SystmOne. 
This gives confidence in using this resource for healthcare research into IBD.  
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5.2 Introduction 
Electronic health records from primary care databases (PCD) are an important 
resource for biomedical research. They allow the analysis of large research cohorts, long-term 
trends and investigation into rare outcomes. In the United Kingdom (UK) they enable 
research studies of population cohorts as >98% of UK residents are registered with a GP as 
the gatekeeper for healthcare services. (Lis and Mann, 1995)  
ResearchOne is one such database which was created in 2014, and includes de-
identified clinical records on ~6 million patients from the SystmOne database. (Burr et al., 
2018b) Despite the growing use of electronic datasets as research tools there are uncertainties 
around data quality, data completeness and the potential for unrecorded confounding factors 
to introduce bias. Any compromise in the quality, or completeness of the data could result in 
spurious conclusions being drawn. It is therefore important that before studies are performed 
using these datasets, the data is checked for validity. Data are sparse on the validity of 
chronic disease diagnoses within primary care databases and the SystmOne database has not 
been externally validated to our knowledge to date.   
5.1 Potential validation methods 
There are several methods that have been employed to validate PCDs. Studies have 
compared results from observational studies performed on a PCD with results from 
randomised controlled trials with the same hypothesis. This may not always be appropriate as 
the populations enrolled within clinical trials do not always reflect a more general population 
due to inclusion criteria within the studies. Further methods of validation have been 
undertaken to compare PCD data with National validated registries such as National cancer 
registries and UK hospital episode statistics (HES). The potential problem with this method is 
that the episodes recorded in cancer registries and hospital procedures are not usually 
included in GP quality performance measures and prioritised for coding. Another validation 
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method is to compare results from one dataset with a similar PCD. This, again, has been used 
to compare other UK databases such as CRPD and THIN (Reeves et al., 2014) and has shown 
good concordance. Another validation method has been to use GP questionnaires to compare 
PCD with hospital letters and discharge summaries also held on the PCD, although not coded. 
This method is limited by the response rate from the GP and the quality and quantity of data 
sent through to them from secondary care. Rare diseases, and those predominantly managed 
in secondary and tertiary care centres are most likely to be misclassified on GP databases as 
the entries are transposed from discharge summaries and clinical letters. They are also less 
likely to be included in the GP contract codes. It is therefore important that PCD data for such 
conditions is validated in order to use these data for research purposes. 
To date there has been no prior validation study of the data held within the SystmOne 
and therefore the ResearchOne PCD to my knowledge.  
5.1.1 Aim 
Here, I explore the validity of IBD diagnoses within the SystmOne primary care 
database in individuals recruited from hospital out-patient clinics.  
5.2 Materials and methods 
Patients were recruited from IBD out-patient (OP) clinic attendances at Leeds 
Teaching Hospital NHS Trust, UK. Written, informed consent was obtained by members of 
the research team (NB, VS).  Information was recorded on IBD type, CD, UC or 
indeterminate colitis (IBD-U). The first recorded date of IBD diagnosis was obtained from 
hospital clinical records, including clinic letters, and histopathology results. Surgical 
information was recorded for the first gastrointestinal resection and the type of operation 
performed. Operations were classified as small bowel resection, ileo-colonic resection, 
colonic resection and total colectomy. The hospital records were taken as the reference 
standard for the study. 
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Primary care recorded entries were taken as the first recorded Read code entry for 
IBD and the number, type and date of the first recorded, IBD-related surgery. Where there 
were multiple different Read code entries for IBD I classified the IBD diagnoses as follows;  
• CD – CD Read codes only or IBD-U followed by CD Read code. 
• UC – UC Read codes only or IBD-U followed by UC Read code. 
• IBD-U – IBD-U Read codes only or a combination of CD & UC Read codes. 
Patient records from SystmOne were used for my primary analyses. In my secondary 
analyses I recorded information from any other different primary care databases and pooled 
the data. I aimed to recruit 100 patients with IBD, and data held on the SystmOne primary 
care database. This is in line with previous validation studies from different datasets (Aberra 
et al., 2005; Herrett et al., 2010) and would give enough patients to draw a meaningful 
conclusion about the accuracy of the database.  
5.2.1 Statistical analyses 
Continuous variables were presented as medians with interquartile range (IQR) for 
non-parametric and means with standard deviations (SD) for parametric variables. I 
compared the percentage accuracy between the SystmOne database and all other recorded 
primary care databases using a paired t-test. 
I considered p values of  <0.05 to be statistically significant. I used Stata 14 
(StataCorp LP, College Station, TX, USA) for all our analyses. 
5.2.2 Ethical statement 
The study was approved by the North West - Liverpool Central Research Ethics 
Committee and the NHS health research authority (REF: 16/NW0076). Approval documents 
are included in the appendix (Appendix 4) 
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5.3 Results 
I recruited and consented 147 patients with IBD from outpatient clinics at Leeds 
Teaching Hospitals NHS Trust (Table 5). Of these, 100 patients were registered with a 
SystmOne GP practice and included in the primary results. From the hospital histological 
diagnoses there were 62 patients with CD, 35 with UC and three with indeterminate colitis. 
There were 23 individuals who had undergone a GI surgical resection for IBD, 61% of these 
were ileo-colonic resections (Table 5).  
The results of the validation are shown in Table 6. IBD diagnoses were recorded in 98 
(98%) individuals’ SystmOne GP records.  The type of IBD was correct in 93% of 
individuals with no difference between SystmOne and all other GP computer systems (p = 
0.50). The IBD diagnosis was within 6 months for 76% and within 12 months for 85% of 
individuals. Again, there was no difference between SystmOne and other GP computer 
systems (p = 0.88 and p = 0.77, respectively). Individuals who had undergone surgery was 
recorded in 91% of patient’s primary care records. The surgery type was correct in 81% of 
cases. The surgery date was accurate within 6 months in 90% of cases and within 12 months 
in 95% of cases.  
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Table 5 Inflammatory bowel disease patients and gastrointestinal 
surgery resections included in a validation study of the SystmOne 
primary care database. 
 
SystmOne, n (%) SystmOne and EMIS combined, n 
(%)   
 
Inflammatory bowel disease 100 147  
Crohn's disease 62 (62) 86 (58) 
Ulcerative colitis 35 (35) 57 (39) 
Indeterminate colitis 3 (3) 4 (3) 
 
 
 
Surgery 23  32  
Small bowel resection 2 (9) 2 (6) 
Ileo-colonic resection 14 (61) 22 (69)  
Colonic resection 0 (0) 1 (3) 
Total colectomy 7 (30) 7 (22) 
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Table 6 Validation of inflammatory bowel disease diagnoses held 
within the primary care databases SystmOne, and pooled primary 
care databases compared to the reference standard of hospital medical 
records. 
 
SystmOne, n (%)   
SystmOne and EMIS 
combined, n (%)   
IBD diagnoses  
 
 
IBD diagnosis recorded in primary care record 98 (98) 144 (98) 
IBD diagnosis correct, n (%) 92 (93) 137 (94) 
Difference in IBD diagnosis date, median days (IQR) 38 (4 - 188) 34 (6 - 194) 
IBD diagnosis date correct within 6 months, n (%) 75 (76) 110 (75) 
IBD diagnosis date correct within 12 months, n (%) 84 (85) 123 (84) 
 
 
 
Surgical diagnoses  
 
 
First GI surgery recorded on primary care record, n (%) 21 (91) 28 (88) 
First GI surgery type correct, n (%) 17 (81) 22 (79) 
Difference in surgery date, median days (range) 0 (0 - 2922) 0 (0 - 2922) 
First GI surgery date correct within 6 months, n (%) 18 (90) 24 (92) 
First GI surgery date correct within 12 months, n (%) 19 (95) 25 (96) 
 
IBD – inflammatory bowel disease; GI – Gastrointestinal; IQR – inter-quartile range. 
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5.4 Discussion 
There is increasing use of PCDs for epidemiological research studies into population 
health. There is a need to validate these databases for the accuracy of clinical data within 
them to justify their continued use. Here I have shown that the SystmOne database has good 
accuracy for IBD diagnoses and associated GI resectional surgery that are recorded in 
hospital notes.   
There have been previous studies examining the validity of UK primary care 
databases employing different methodologies to give a positive predictive value of a primary 
care recorded entry. (Soriano et al., 2001; Herrett et al., 2010) My results are in concordance 
with a study by Lewis et al who compared GPRD primary care data with data from GP 
questionnaires. (Lewis et al., 2002) Here, IBD diagnoses were shown to be accurate in 92% 
of cases. A systematic review and meta-analysis of diagnostic coding in UK primary care 
computerised datasets found an overall median accuracy of 89%, which is also in line with 
my results. (Herrett et al., 2010) I have also shown that the dates of diagnoses are accurate to 
within 12 months. This is an important finding as epidemiological investigations using 
primary care datasets will often seek to investigate long-term outcomes in longitudinal, 
observational studies. It is important therefore to have an accurate start point to investigate 
the clinical disease course.  
Previous studies have used computerised searches of primary care data or 
questionnaires to general practitioners to confirm cases, often without additional information 
from hospital records. This introduces a potential bias as primary care practitioners are 
validating their own clinical entries. My study uses hospital data as the reference standard. 
IBD is typically diagnosed and managed in secondary care after endoscopy and histology 
(Mowat et al., 2011) so I believe that this is a robust way of confirming a diagnosis of IBD. 
- 80  
I selected consecutive patients from out-patient clinic lists on different days and 
expect the results of this study to be generalisable to the remainder of the SystmOne database 
and other UK databases as SystmOne GPs are not pre-selected and should be representative 
of primary care practitioners.  
I included a relatively small sample size of 100 patients from the SystmOne database, 
and only 23 of these had undergone a GI surgical resection for IBD which may limit the 
accuracy of the final estimates for our secondary outcome.  A systematic review of validation 
studies of a similar dataset, the General Practice Research Datalink (now called the Clinical 
Practice Research Datalink) in 2010 included 347 studies. (Herrett et al., 2010) Here, the 
median number of cases reviewed was 104, which is consistent with my study. A further 
limitation is that I could not verify the positive predictive value of the accuracy of IBD 
diagnoses on primary care records as I approached the validation from secondary care 
records. This is an important consideration for IBD diagnoses that are made in primary care. 
However, I expect this scenario to be unlikely for conditions such as IBD that are typically 
diagnosed after colonoscopy, performed in secondary care centres with subsequent 
management being co-ordinated through dedicated hospital clinics. Studies have shown that 
over a third of patients are solely managed in secondary care services in the UK. (Stone, 
Mayberry and Baker, 2003) The latest estimates, albeit from the 1990’s, showed that there 
were only 26 consultations per 100,000 population per year for IBD related symptoms in 
primary care which strengthens my hypothesis that most cases of IBD are managed 
predominantly in secondary or tertiary care settings. (Clinical Effectiveness and Evaluation 
Unit, 2014)  
CD can occur at any location in the GI tract and UC at different colonic locations. 
This level of detail is not recorded in primary care databases, so I was unable to further 
explore location of IBD in this study.  
- 81  
5.5 Conclusions 
There is increasing use of large-scale population datasets for epidemiological 
research. A concern with using these datasets is the accuracy of information held in them. 
Here, I have shown that IBD diagnoses recorded in hospital records are correct for 93% of 
patients on the SystmOne database, giving validity to research studies using this data source.  
ResearchOne is a novel, ethically approved dataset that comprises a subset of ~6million 
individual clinical records from SystmOne. This information is de-identified and so cannot be 
externally validated but I expect our results to be generalisable to this dataset as the records 
are not pre-selected for inclusion. IBD is typically diagnosed and managed from secondary 
care facilities in the UK.  It is reasonable to assume that other chronic diseases will have 
similar coding accuracy to the estimates I have made for IBD.   
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Chapter 6: Description of the IBD cohort in the ResearchOne database 
In this chapter I will describe the IBD cohort obtained from the ResearchOne primary 
care dataset and used for the remainder of the analyses in this thesis. I will also describe the 
aetiological factors associated with IBD-CRC and furthermore describe the trends in 
diagnosis of CRC in this population.  
6.1 Data sources and participants 
The primary care database ResearchOne was used for this study. 
(www.researchone.org) This is described in detail in prior chapters but includes information 
from the electronic health records of approximately 6 million individuals (>10% of the total 
population) in England.   
6.1.1 Inclusion and exclusion criteria 
I included all adults (>18 years old) at the extraction date (14th September 2014) with 
a Read code for IBD in their primary care record (Appendix 1). Individuals were classified as 
CD and ulcerative colitis UC when only Read codes for these IBD subtypes were recorded. I 
defined a third category of IBD-U as those with a specific code for this entity or where there 
were both codes for UC and CD in the individual’s GP medical record. For all individuals, I 
extracted a defined set of data items, including; date of birth (mm/yyyy), sex, date of death 
(mm/yyyy), GP registrations, Index of Multiple Deprivation (IMD) of residence, (Noble, 
Mclennan and Wilkinson, 2007) diagnoses of IBD and relevant comorbidities (including 
smoking status), ethnicity, and prescriptions (including repeat prescriptions).  British 
National Formulary (https://www.evidence.nhs.uk/formulary/bnf/current (accessed April 
2014)) headings and subheadings were used to identify the medication classes.  Individuals 
were followed up from their IBD diagnosis to either death or the extraction date. 
I defined an incident cohort as those who had been diagnosed with IBD at least twelve 
months after joining a ResearchOne practice. This excludes prevalent cases where the date of 
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diagnosis may be less accurate. This also allows the capture of continuous prescription and 
clinical data from the date of entry into the ResearchOne database. 
6.1.2 Covariates 
Age at diagnosis was categorised into groups as follows: < 30 years, 31 to 40, 41 to 
50, 51 to 60, 61 to 70, and over 70 years. Duration of IBD was categorised as follows: 0 to 2 
years, > 2 years to 4 years, > 4 years to 6 years, > 6 years to 8 years, > 8 years to 10 years, 
and > 10 years. Individuals were also classified into cohorts depending on the year of IBD 
diagnosis to account for changes in disease phenotype and management that might affect 
outcomes. Year of diagnosis cohorts were as follows: before 1993, from 1994 to 2000, from 
2001 to 2007, and from 2008 to 2014.  
Social deprivation score was included as five groups, based on equal quintiles of the 
IMD score. A higher IMD score equates to more deprivation and has been shown to correlate 
with increased morbidity and all-cause mortality in the UK. (Marmot et al., 2010) To account 
for co-morbidity I produced an estimate of the Charlson score (Charlson et al., 1987) using 
Read codes for each of the seventeen weighted disease categories included in the original 
score. I calculated a similar, weighted score and used a cut off of  ≥ 2 as a modest estimate of 
co-morbidity. Smoking history was recorded as ever smoked, never smoked and smoking 
data missing. The hierarchy of smoking data was:  0 “never smoked”, 1 “missing smoking 
data”, and 2 “ever smoked”. This ordering for the hierarchy was used as it is assumed that 
some of individuals with missing smoking data will have smoked. I adjusted for known 
surrogate markers of CD severity including corticosteroid medications given within ninety 
days of IBD diagnosis (Peyrin-Biroulet et al., 2012) and also immunomodulator use, namely 
azathioprine, 6-mercaptopurine and methotrexate. (Picco et al., 2009) 
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6.1.3 IBD-CRC epidemiology cohort 
I included all individuals with a Read code diagnosis for CRC (Appendix 2). 
Individuals who had undergone a colectomy for UC were excluded as they have much 
reduced chance of developing CRC. I described the demographics of the IBD-CRC using the 
covariates listed above. Again, as above I created an incident cohort comprising those who 
were diagnosed with IBD at least one year after joining a ResearchOne GP practice. To 
explore the geographical spread of the IBD population held within the ResearchOne database 
I plotted the location of each general practitioner location with an individual with an IBD 
diagnosis. 
6.1.4 Trend analysis 
I explored the trend in cancer cases depending on the year of IBD diagnosis to see if 
there has been any change in the rate of diagnosis over time. I used chi2 for trend as a 
significance test. The numerator in this analysis was the number of CRC cases diagnosed in a 
particular time period. The denominator was the total number of living IBD cases within each 
time period excluding those who had an earlier coded entry for CRC.  I performed a subgroup 
trend analysis of only those diagnosed after the year 1990 as I used 1990 as a cut-off for the 
start of the year cohorts. 
Any change in the trend in diagnosis of IBD-CRC in the ResearchOne database 
throughout the study period is likely to be associated with the overall age of the ResearchOne 
cohort. This is because increasing age is a such a strong risk factor for the development of 
CRC. To display this association, I produced a line graph of the mean age of the alive, 
registered cohort throughout the study period from 1990. Again, chi2 for tend was used as a 
significance test. 
6.1.5 Ethical statement 
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ResearchOne has received a favourable opinion from National Health Service (NHS) 
Research Ethics Committee (REC) (11/NE/0184) and the UK National Information 
Governance Board for Health and Social Care.  Our study has NHS REC (14/WM/01/26) and 
local research and development (GA14/11077) approval. Approval documents are included in 
the appendix. (Appendix 4) 
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6.2 Results 
6.2.1 Description of the ResearchOne IBD cohort 
There were 17,883 adults (>18 years) with a diagnosis of IBD, (6,077 CD, 9,442 UC 
and 2,364 with indeterminate colitis). Full characteristics are shown in table 7. For all IBD 
subtypes there was a small difference in sex, with 51% of the cohort being female. When 
stratified by IBD subtype there was a difference for CD with 54% being female (p < 0.01). 
For UC there were significantly more males, 52% (p < 0.01). The median duration of IBD for 
those included was 9 years (IQR 4 to 15 years) for our entire cohort and 7 years (IQR 3 to 12 
years) for our incident cohort, diagnosed at least one year after joining a ResearchOne 
practice.  I plotted the geographical location of General Practices in the United Kingdom with 
patients with IBD and included on the ResearchOne database. (Figure 9) This shows that the 
cohort is distributed throughout the UK, with predictable concentrations in areas with known, 
high population densities, such as the South East of England and London area. There is also a 
cluster of increased density in Northern England. 
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Table 7 Table of characteristics of the IBD population held within the 
ResearchOne Primary care database. Entire cohort and incident 
cohort. 
  Entire cohort Incident cohort 
    n % n % 
Total 17,883  10889  
      
IBD subtype Crohn's disease 6077 34.0 3517 32.3 
 Ulcerative colitis 9442 52.8 5641 51.8 
 Indeterminate colitis 2364 13.2 1731 15.9 
     
Sex Male 8784 49.1 5396 49.6 
 Female 9099 50.9 5493 50.4 
     
Age at diagnosis under 20 years 5445 30.4 2294 21.1 
 over 20 to 30 years 3535 19.8 1983 18.2 
 30 to 40 years 2931 16.4 1996 18.3 
 50 to 60 years 2416 13.5 1775 16.3 
 60 to 70 years 1898 10.6 1512 13.9 
 over 70 years 1658 9.3 1329 12.2 
      
Year of IBD 
diagnosis before 1993 2526 14.1 629 5.8 
 after 1993 to 2000 2260 12.6 1036 9.5 
 after 2000 to 2007 5907 33.0 3683 33.8 
 after 2007 to 2014 7190 40.2 5541 50.9 
      
IBD duration 
(years) 0 to 2 years 1392 7.8 1196 11.0 
 > 2 years to 4 years 2194 12.3 1782 16.4 
 > 4 years to 6 years 1948 10.9 1451 13.3 
 > 6 years to 8 years 1928 10.8 1361 12.5 
 > 8 years to 10 years 1699 9.5 1140 10.5 
 > 10 years 8722 48.8 3959 36.4 
      
Smoking Never smoked 8834 49.4 5307 48.7 
 
Smoking data 
missing 1038 5.8 595 5.5 
 Ever smoked 8011 44.8 4987 45.8 
      
IMD income 
category 
Most affluent 3587 
20.1 2052 18.8 
 2 3618 20.2 2224 20.4 
 3 3551 19.9 1983 18.2 
 4 3562 19.9 2292 21.0 
 Least affluent 3565 19.9 2338 21.5 
   
   
Charlson score ≥ 2 No 14433 80.7 8724 80.1 
 Yes 3450 19.3 2165 19.9 
 
IBD – inflammatory bowel disease; IMD – index of multiple deprivation. 
Incident cohort is those diagnosed at least one year after joining a ResearchOne GP practice  
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Figure 9 Map of the United Kingdom with location of GP practices 
with IBD patients held within the ResearchOne primary care database 
 
Each dot represents a general practice in the United Kingdom with a patient with IBD in the ResearchOne 
primary care database. The solid boundaries represent administrative counties in the UK. 
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6.2.2 Characteristics of the ResearchOne IBD-CRC dataset 
The demographics of the ResearchOne IBD-CRC dataset is shown in Table 8. After 
restricting those who had a colectomy, there were 250 cases of colorectal cancer and 16,434 
controls, without the disease, with a median IBD duration of 9 years. In the incident cohort of 
patients with IBD there were 146 cases of CRC and 10,183 controls without CRC, with a 
median IBD duration of seven years. More of the CRC cases were male (60% versus 40% 
female). When stratified by age category at diagnosis of IBD, CRC cases were younger (p 
<0.01). There were more individuals with CRC and a history of smoking in both the entire 
(48% in cases versus 44.9% in controls) and incident (50.7% in cases versus 45.6% in 
controls), with 7.2% of CRC cases with missing smoking data in the entire cohorts and ~6% 
missing data in all other groups.  Deprivation scores were comparable in the entire and 
incident cohorts, with a higher proportion in the most affluent and least affluent groups for 
CRC cases. In the entire cohort 36% of CRC cases (n = 90) were diagnosed with less than 
eight years of recorded disease, taken as their first recorded entry of IBD in their primary care 
record. In the incident cohort this proportion was even higher with 51% (n = 74) being 
diagnosed with less than eight years of recorded disease. Comorbidity scores were 
significantly higher in CRC cases in both the entire and incident cohorts. 
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Table 8 Demographics of the IBD CRC cohort and incident cohort within the ResearchOne primary care 
database 
  Entire cohort Incident Cohort 
  Controls 
Colorectal cancer 
cases  Controls 
Colorectal cancer 
cases  
    n % n % p-value n % n % p-value 
Total  16434  250   10183  146   
            
IBD type Crohn's disease 5729 34.9 72 28.8  3363 33.0 43 29.5  
 Ulcerative colitis 8446 51.4 148 59.2  5156 50.6 81 55.5  
 
Indeterminate 
colitis 2259 13.7 30 12.0 0.05 1664 16.3 22 15.1 0.51 
Sex           
 Male 8027 48.8 150 60.0  5013 49.2 87 59.6  
 Female 8407 51.2 100 40.0 <0.01 5170 50.8 59 40.4 0.01 
           
Year of IBD 
diagnosis Before 1993 2127 12.9 74 29.6  546 5.4 14 9.6  
 1993 - 2000 2008 12.2 25 10.0  926 9.1 11 7.5  
 2000 - 2007 5389 32.8 82 32.8  3369 33.1 66 45.2  
 2007 - 2014 6910 42.0 69 27.6 <0.01 5342 52.5 55 37.7 <0.01 
            
Age at diagnosis under 20 years 4929 30.0 46 18.4  2156 21.2 9 6.2  
 > 20 to 30 years 3262 19.8 30 12.0  1871 18.4 10 6.8  
 30 to 40 years 2698 16.4 38 15.2  1859 18.3 18 12.3  
 50 to 60 years 2232 13.6 36 14.4  1650 16.2 26 17.8  
 60 to 70 years 1762 10.7 47 18.8  1408 13.8 39 26.7  
 > 70 years 1551 9.4 53 21.2 <0.01 1239 12.2 44 30.1 <0.01 
            
IBD duration 
(years) 0 to 2 years 1353 8.2 22 8.8  1162 11.4 19 13.0  
 > 2 years to 4 years 2117 12.9 26 10.4  1724 16.9 19 13.0  
 > 4 years to 6 years 1865 11.3 24 9.6  1389 13.6 20 13.7  
 > 6 years to 8 years 1820 11.1 18 7.2  1287 12.6 16 11.0  
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> 8 years to 10 
years 1582 9.6 20 8.0  1069 10.5 16 11.0  
 > 10 years 7697 46.8 140 56.0 0.07 3552 34.9 56 38.4 0.78 
            
Smoking Never smoked 8093 49.2 112 44.8  4967 48.8 64 43.8  
 
Smoking data 
missing 966 5.9 18 7.2  568 5.6 8 5.5  
 Ever smoked 7375 44.9 120 48.0 0.32 4648 45.6 74 50.7 0.47 
            
IMD income 
category 
Most affluent 3256 
19.8 68 27.2  1898 18.6 38 26.0  
 2 3315 20.2 41 16.4  2075 20.4 23 15.8  
 3 3276 19.9 49 19.6  1868 18.3 26 17.8  
 4 3306 20.1 38 15.2  2164 21.3 25 17.1  
 Least affluent 3281 20.0 54 21.6 0.02 2178 21.4 34 23.3 0.13 
   
         
Charlson score ≥ 2 No 13308 81.0 182 72.8  8182 80.3 105 71.9  
 Yes 3126 19.0 68 27.2 <0.01 2001 19.7 41 28.1 0.01 
 
IBD – inflammatory bowel disease; IMD – index of multiple deprivation. 
Incident cohort is those diagnosed at least one year after joining a ResearchOne GP practice 
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6.3 Trend in CRC diagnosis 
Figure 10 shows the trend in diagnosis of CRC in our IBD cohort each year, with 
separate trend lines for each IBD subtype. There has been an increase in CRC cases in the 
ResearchOne database through the study period from 1990 to 2013 for each IBD subtype.  
This did not reach significance for those with UC but was significant for all CD and all IBD 
combined (Chi2 for trend p < 0.05). Figure 11 shows the mean age of the ResearchOne IBD 
cohort over the same time period. There was a significant increase throughout the time period 
from an average age of 37 years in 1990 to 51 years in 2013 (Chi2 for trend p < 0.05). 
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Figure 10 Proportion of the ResearchOne IBD cohort diagnosed with CRC each year: Stratified by IBD subtype 
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Figure 11 Mean age of those alive and registered in the ResearchOne database 1990 to 2013 
 
 
Note: Chi2 for trend (p < 0.05) 
Entire cohort used 
0
10
20
30
40
50
60
M
ea
n
 a
g
e 
in
 y
ea
rs
Year
- 96  
6.4 Discussion 
Here, I have confirmed associations with IBD-CRC and male sex, increasing age, 
increasing disease duration and increased co-morbidity. The overall number of IBD-CRC 
cases in the ResearchOne database is increasing over time but the average age of the cohort is 
also increasing which is likely to be attributing to the increase in CRC.  
There have been several recent studies that have attempted to estimate the risk of 
CRC in those with IBD and compare it to the “sporadic” CRC population. Many of the 
results are heterogenous because of the varied populations used and mixes of primary and 
secondary care studies. Increased risk estimates from previous studies are at anywhere 
between 1 and 30 times compared to the general population. (Lutgens et al., 2013; Castano-
Milla C. Chaparro M. Gisbert J.P. et al., 2014; Laukoetter et al., 2011; Eaden, Abrams and 
Mayberry, 2001) 
There are varying reports on the temporal trends of IBD-CRC. A Danish study 
indicated that the incidence of CRC in those with UC may be decreasing. (Jess et al., 2012) 
This was also shown in a systematic review and meta-analysis in 2013, (Castano-Milla C. 
Chaparro M. Gisbert J.P., 2014) which showed a decreased incidence rate from 4.29/1000 
patient years for studies in the 1950’s to 1.21/1000 patients years for studies since 2000. 
These results may be affected by the rate of colectomy in the different countries. Historically, 
these rates have been higher in Scandinavian countries which could explain some of the 
reduced rates in these jurisdictions. (Frolkis et al., 2013) However, in line with the small but 
significant increase seen in this study, results from the USA and Sweden show a small 
increase in the rate. As the prevalence of IBD is increasing worldwide, regardless of whether 
there are small changes in the temporal incidence either way, there will be an increased 
prevalence and overall burden of IBD-CRC. It therefore remains important to characterise 
risk-factors for the disease to target appropriate screening and surveillance strategies.   
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I have shown that those with longer disease duration were more likely to develop 
IBD-CRC with 56% of cases having disease for longer than ten years compared to 47% of 
controls.  Duration of disease is an established risk factor for IBD-CRC, as prolonged 
inflammation leads to the increased chance of mutations that can lead to malignancy. (Adami 
et al., 2016) A landmark study from Eaden et al. from studies pre-dating the year 2000 
showed that cumulative CRC incidence was 8% by 20 years and 18% by 30 years of disease. 
(Eaden, Abrams and Mayberry, 2001) More contemporary results report much more 
conservative estimates with a meta-analysis of four population based studies estimating a risk 
of 0.8% at 10 years, 2.2% at 20 years and 4.5% after > 20 years. (Lutgens et al., 2013) I have 
also shown that a large proportion of IBD-CRC cases were diagnosed before eight years of 
recorded disease, 36% in the entire cohort and 51% in the incident cohort. This is an 
important observation as societal guidelines advocate a screening colonoscopy after 8, or 10 
years of disease duration. (Lamb, 2019; Cairns et al., 2010) It is difficult to accurately 
determine the true duration of disease in routine collected datasets from primary or secondary 
care as they rely on the first recorded entry in a medical record. The mucosal inflammation 
from IBD may be present for a prolonged period before a patient presents to primary or 
secondary care and ultimately undergoes investigation such as endoscopy to confirm the 
diagnosis. This date may be erroneously recorded as the onset time of disease, when the true 
onset may have been months or years earlier. 
The finding that a large proportion of IBD-CRC occurs in those without longstanding 
colitis (< eight years of disease) is in line with prior studies. In a study from St Mark’s 
Hospital in the UK, and a Danish population cohort, duration of disease was not shown to be 
an independent risk factor for the development of IBD-CRC. (Choi et al., 2015a; Jess et al., 
2012) These results taken together with our own could have an implication on societal 
guidelines for the timing of the initial screening test, and interval for further surveillance. 
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Currently the recommendation for an index test at eight to ten years and then up to five-
yearly based solely on duration may not be appropriate. A further study from the St Mark’s 
group investigated the potential effects of colonic inflammation, and cumulative 
inflammatory burden on the development of IBD-CRC. (Choi et al., 2019) In this study, the 
cumulative inflammatory burden was calculated by multiplying the average inflammation 
score on consecutive colonoscopies by the length of surveillance interval. From a cohort of 
97 IBD-CRC cases they showed that an increase in the mean severity of inflammation score 
over the preceding 5 colonoscopies was significantly associated with increasing risk of CRC 
with a HR of 2.2 per 1-unit increase (p <0.001).  This is intuitive as it is the presence of 
longstanding inflammation that is the likely driver of malignant transformation. As most of 
these studies pre-date the widespread use of more aggressive treatments to control 
inflammation, and reduce risk, these may still overestimate the true risk if IBD-CRC. Those 
with mucosal healing, and quiescent disease are unlikely to be at any greater risk than the 
background population. Future guidelines should incorporate the duration of active 
inflammation and not just the duration since diagnosis. This could be classified as the 
cumulative inflammatory burden as in the St Marks study above. (Choi et al., 2019)   
In my results, cases of IBD-CRC were older at diagnosis in both the entire cohorts 
and incident-1yr cohorts, with over 40% (entire) and over 50% (incident) being over the age 
of 60 at diagnosis compared to 20% and 25% of those without CRC.  Increasing age is an 
established risk factor for sporadic CRC and is also seen in IBD-CRC. As I did not have a 
control group of sporadic CRC, I was unable to compare relative risk of CRC in different age 
groups compared to the risk in each of these age groups in those without IBD. In prior meta-
analyses the pooled standard incidence ratio of IBD-CRC was 8.2 amongst those less than 30 
and 1.8 in those older than 30. (Lutgens et al., 2013) Young age at onset of IBD is associated 
with higher risk of CRC. A Danish population-based study estimated the increased risk at 
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43.8 for those with IBD diagnosed between the ages of 0 and 19. The SIR was 2.65 for those 
diagnosed between ages 20-39 and lower for those diagnosed after the age of 60 years. (Jess 
et al., 2012)  
I have shown that male sex is a significant risk factor associated with the development 
of IBD-CRC. This is consistent with prior studies. In the same Lutgens meta-analysis of 
contemporary studies in 2012 there was a pooled increased standardised incidence ratio of 
IBD-CRC of 1.9 in men and 1.4 in women. (Lutgens et al., 2013)  
I did not find a significant positive association between a recorded history of smoking 
and IBD-CRC in any of our analyses. This is consistent with other studies investigating IBD-
CRC. (Velayos et al., 2006) A potential theory is that smoking, and in particular nicotine may 
suppress colonic inflammation. (Pullan et al., 1994; Sandborn, 1997) 
Using primary care data is useful for estimating population risks of disease, as 
secondary or tertiary care data are likely to include those with more advanced, aggressive 
disease with a higher risk of CRC. Primary care populations, such as here, are more likely to 
give a closer approximation of the true incidence, as they should include a greater spectrum 
of disease. I censored those who had undergone a colectomy before a diagnosis of CRC, as 
this would affect our risk estimate as these patients are highly unlikely to develop CRC.  
I was unable to investigate associated risk factors for IBD-CRC due to lack of detail 
in the ResearchOne database. These include; extent of disease, severity of disease, family 
history, obesity and history of primary sclerosing cholangitis.   
The increased incidence of IBD-CRC could be due in part to lead-time bias. IBD 
patients are more likely to undergo regular investigations of their colon either as part of IBD 
disease assessment or surveillance for CRC. This can lead to overdiagnosis, in detecting CRC 
incidentally that would never have manifested otherwise. This bias is particularly important 
- 100  
in survival analyses conducted on similar datasets. Another reason for an apparent increase in 
IBD incidence through the study period could be explained by the increasing age in the 
cohort. There was a significant increase in the average age throughout the study period, so 
this is likely to have an influence on the increase in IBD-CRC. Future analyses should 
consider age standardised incidence ratios to explore this association further.  
 Whilst duration of disease is an important association with IBD-CRC, there were a large 
number who developed CRC before 8 years from the first recorded diagnosis which has 
implications for future surveillance guidelines. The ResearchOne IBD cohort shares 
characteristics with established cohorts of IBD and IBD-CRC cases which gives confidence 
in using it as a resource for epidemiological  research. The limitations of using these 
resources is that diagnoses are recorded from primary care and are not verified. Ideally, 
linked datasets would be made available that would combine the rich population data, and 
prescription data with hospital clinical records to include more disease specific data to define 
any associations more precisely.
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Chapter 7: Chemoprevention of CRC in Inflammatory bowel disease using 
routinely prescribed drugs 
7.1 Introduction 
The aim of these nested case-control studies was to investigate if there is an inverse 
association between the use of routinely prescribed drugs and the development of IBD-CRC. 
Demonstrating such an association would emphasise the need to record these drugs in future 
studies investigating IBD-CRC and support their assessment as chemopreventative agents in 
prospective randomised controlled trials in patients at high risk of the disease.  
7.2 Methods  
7.2.1 Data sources and participants 
The primary care database ResearchOne was used for this study. 
(www.researchone.org) As described, ResearchOne holds de-identified clinical and 
administrative information from the electronic health records of approximately 6 million 
individuals (>10% of the total population) in England.  For this study I used the IBD-CRC 
dataset as described in Chapter 6. 
7.2.2 Drug use definitions  
Drug use was taken from recorded prescriptions in the ResearchOne database before a 
diagnosis of CRC for cases and in the entire follow up period for control. I defined drug users 
and non-users based on the number of independent prescriptions of each drug that they had 
been issued. Drug users were those with at least 3 prescriptions of each drug. A prescription 
from primary care in the UK is typically for a 28 day course. (Foy et al., 2016) Aspirin, 
statins and antiplatelet medications are typically prescribed for chronic disease and so I 
would not routinely expect these to be discontinued. Additionally, individuals were only 
defined as drug users if they had been prescribed the medication for at least one year before a 
diagnosis of CRC for enough time to have elapsed to exert any potential chemopreventative 
effect. Non-users were those who had never been prescribed the drug, had less than 3 
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prescriptions in total, or had been prescribed the drug for less than one year as a conservative 
definition. This may reduce any associations identified, but it is expected that at least a year 
of drug use would plausibly be required to prevent early cancer development. I used a 
dichotomous definition of low and high dose of statins depending on whether the medication 
strength was greater or ≤ than one “defined daily dose” of the drug. The defined daily dose is 
an international unit that aids comparison of drugs in the same class. One defined daily dose 
is taken as the average maintenance daily dose of a medication. (Wertheimer, 1986) Where 
an individual had been prescribed both low and high dose statins, they were restricted from 
the subgroup analyses. The statins were also further divided into lipophilic and hydrophilic 
drugs. Where an individual had been prescribed both lipophilic and hydrophilic statins, they 
were restricted from the subgroup analyses to try and determine whether there was a different 
association depending on the drug lipophilicity.   
7.2.3 Drugs included. 
I included all forms and versions including generics and originator equivalents of each 
medication class as follows:  
• Aspirin.  
• Non-aspirin antiplatelet drugs included: clopidogrel, dipyridamole, and ticagrelor.  
• NA-NSAIDs included: diclofenac, ketoprofen, etoricoxib, etodolac, azaproprazone, 
piroxicam, ibuprofen, celecoxib, sulindac, lumaricoxib, mefenamic acid, meloxicam, 
nabumetone, naproxone, etodolac, etoricoxib, fenbrufen, flurbiprofen, indomethacin, 
rofecoxib, tolfenamic acid, and voltarol.  
• Statins: 
o Lipophilic statins included: simvastatin, lovastatin, atorvastatin, and 
fluvastatin.  
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o Hydrophilic statins included: pravastatin and rosuvastatin. 
• 5-aminosalicylate medications included: balsalazide, colazide, mesalazine, olsalazine 
and sulfasalazine. These were then categorised depending on the preparation type 
into: “Oral”, “rectal”, and “oral or rectal”. 
• Immunomodulator medications included: azathioprine, 6-mercaptopurine, and 
methotrexate.  
• Corticosteroids included: budesonide, prednisolone, methylprednisolone, and 
hydrocortisone. 
7.2.4 Covariates 
All covariates were as defined in Chapter 6 and included: date of birth, IBD subtype 
(UC, CD and indeterminate), sex (male, female), Year of IBD diagnosis in 7-year cohorts, 
Age at IBD diagnosis in 10-year bands, IBD duration in years in 2-years bands, smoking 
status (never smoked, smoking data missing, and ever smoked), IMD score (1-5), and 
Charlson co-morbidity score ≥ 2.   
7.2.5 Nested case control analyses 
To explore the potential role of these medications in preventing IBD-CRC I 
performed a series of nested case-control analyses. CRC cases were defined by a Read code 
entry for CRC in their ResearchOne medical record. Controls were those without an entry for 
the disease. A matched case control study was used to control the influence of known 
confounding variables.  A nested case-control study design with matching has been shown to 
be an efficient design that can be used to provide unbiased risk estimates. (Breslow, 1996) 
There are several advantages to using this approach as cases and controls are sampled from 
the same population, exposures are measured prior to the outcome occurring and cases are 
matched to controls at the time of the outcome event. 
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7.2.6 Statistical analysis 
To increase the precision of any association, CRC cases were randomly matched with 
up to 10 controls, without a recorded entry for CRC, to form the analysis cohort.  The 
matched analysis was used to try and account for the influence of several important 
confounding factors that might bias the results. After matching, a conditional estimate of the 
odds ratio for each medication was calculated. The matching variables used in the model 
were: IBD subtype, sex, age at IBD diagnosis cohort, duration of IBD in years cohort, year of 
IBD diagnosis cohort, smoking history, and corticosteroid use within 90 days of diagnosis. I 
excluded cases where no matches could be found. These variables may be associated with 
developing IBD-CRC and were available for use with this ResearchOne dataset. Matching 
using these variables was used to try and produce phenotypically similar individuals in the 
case and control groups. Matching analyses were performed using Stata version 14 (Stata 
Statistical Software: Release 14. College Station, TX: StataCorp LP). 
After matching, univariate analyses were conducted to compare characteristics 
between case and control groups. Conditional logistic regression analyses were then 
performed to produce adjusted OR with 95% CI for IBD-CRC, adjusting for any of the 
variables that remained unbalanced after the matching process.   
7.2.7 Safety of chemopreventative medications 
In order to be considered as a routinely used chemoprevention agent it is important 
that each medication is tolerated with an acceptable risk profile. I performed a series of safety 
analyses using three outcomes as markers of adverse results from the use of these 
medications as follows: 
Independent steroid prescriptions 
I used independent prescription of corticosteroid medications as a surrogate marker 
for a flare of inflammatory bowel disease activity. A similar definition, has been validated in 
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a prior study investigating the relationship between season of the year and flare of IBD. 
(Lewis et al., 2004) In the Lewis study, exclusions were made for those with another 
condition which may necessitate the use of steroids. This was not possible in my study as all 
the relevant Read codes were not available for such an analysis. An independent prescription 
of steroids was defined as a prescription of any corticosteroid medication after a period of 
four months with no such prescription. The last 14 days prior to a flare were excluded as it is 
impossible to say with certainty with routinely collected data, when a person enters a period 
of remission. From the primary care data held in ResearchOne, it is often difficult to 
determine exactly when a patient completes a course of steroids. In the Lewis et al. study, 
(Lewis et al., 2004) using the same definition for prescription of corticosteroid medications, a 
validation study was undertaken. Here, they completed a GP survey involving 150 IBD 
patients who received a new prescription for corticosteroids, the positive predictive value of a 
new prescription for steroids to identify an acute flare of inflammatory bowel disease was 
85% (82 of 96).  
Surgery 
I defined a new surgery as the presence of a Read code for GI resectional surgery 
(Appendix 1) occurring one year after starting a medication namely aspirin, NA-NSAIDs, or 
statins. A time period of one year was allowed so that any potential adverse effect had time to 
develop.  I did not include Read codes for perianal operations, including fistula surgery as 
these may not be related to IBD disease activity. I also excluded codes for reversal, or 
revision, of a previous ileostomy or colostomy as this is likely to represent planned surgery to 
repair the stoma site, rather than for disease activity. (Failes et al., 1979) In the validation 
study (Chapter 5) I found that surgical diagnoses were correct in 91% of cases and the date 
was correct to within 12 months in 95% of cases. 
New prescription of an immunomodulator medication 
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I defined a new prescription of an immunomodulator as any prescription of a 
thiopurine or methotrexate one year after starting a medication, namely aspirin, NA-NSAIDs, 
or statins.  
7.2.8 Statistical methods for the safety analyses 
To ensure that there was correction for relevant variables, I matched cases being 
prescribed each medication of interest with one control, not prescribed the medication based 
on several previously defined variables, namely: age at diagnosis of IBD in 10 year bands, 
type of IBD, duration of IBD, IBD diagnosis cohort in bands, comorbidity score, sex, 
deprivation, and smoking status, and whether corticosteroids were prescribed within 90 days 
of diagnosis or not. The matching was to try and ensure that phenotypically similar 
individuals were accounted for. Conditional logistic regression was then performed to 
calculate OR with 95% CI to compare the odds of each safety outcome for cases prescribed a 
medication of interest and matched controls without such a prescription. Variables included 
in the model were those that remained unbalanced after the matching process.   
7.2.9 Sensitivity analysis 
I composed an incident cohort by excluding those with a date of diagnosis within 
twelve months of joining a ResearchOne practice to exclude prevalent cases where the date of 
diagnosis may be less accurate. This also allows the capture of continuous clinical and 
prescription data from the date of entry into the ResearchOne database. All the analyses were 
repeated on this incident cohort. Separate analyses were performed for CD and UC 
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7.3 Results 
I identified 17,883 individuals with IBD in the entire cohort. After removing 1,199 
who had undergone a colectomy without developing CRC, 16,684 were included in the 
analysis dataset; 5,729 with CD, 8,446 with UC and 2,259 with indeterminate colitis. There 
were more females (8,407 versus 8,027). 37.7% had ever smoked (Table 9).  The median 
average duration of IBD was 9 years. The full description of the CRC cases and controls is as 
detailed in Chapter 6.  
7.3.1 Matched cohort, 10 controls for each case 
The characteristics of the matched cohort are shown in table 9. I aimed to match 10 
controls without CRC for each case with the disease. The cohort included 1,432 controls and 
211 cases with a median IBD duration of 12 years. I was unable to find successful matches 
for 39 (16%) of cases. The matching success rate is shown in table 10. Despite matching, in 
the entire cohort there were significant differences with more CRC cases with indeterminate 
colitis, diagnosed in early or late cohorts, younger at age of diagnosis, and with shorter 
duration of IBD. These variables were then included in the matching model for the 
conditional logistic regression. The incident cohort comprised 746 controls and 119 cases of 
CRC, with a median IBD duration of 8 years. After matching there were significant 
differences with more CRC cases in the later diagnosis cohorts, and more at older age of 
diagnosis, so these variables were including in the logistic regression model for the incident 
cohort.  
Medication use for the matched entire cohort, and matched incident cohort is shown 
in Table 11.  CRC cases were significantly less likely to have been prescribed oral 5-ASA 
drugs, immunomodulator drugs, and high dose statins or (p < 0.05). There were no significant 
associations seen for aspirin, NA-NSAIDs, non-aspirin antiplatelet drugs, low dose statins, or 
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lipophilic or hydrophilic statins analysed individually. Similar associations were seen in the 
incident cohort apart from no significant association for immunomodulators.  
7.3.2 Conditional logistic regression analyses 
Table 12 shows the results for the adjusted conditional logistic regression for the 
entire cohort and incident cohort. CRC cases were significantly more likely to be prescribed 
5-ASA medications, immunomodulators, NA-NSAIDs, NA-antiplatelet drugs, any statin, 
high dose statins and lipophilic statins, all p < 0.05. The only change in association for the 
incident cohort was a borderline association with NA-antiplatelets and IBD-CRC (p = 0.05), 
and no association seen for NA-NSAIDS. There were no significant associations for aspirin, 
low dose statins, or hydrophilic statins when prescribed alone.  
I performed subgroup analyses for CD and UC separately. For CD, significant 
negative associations were seen for 5-ASA medications in the entire and incident cohorts, p 
<0.01. Immunomodulators only had a significant association in the entire cohort. NA-
NSAIDs had a significant negative in the entire cohort and a borderline association in the 
incident cohort. There were no significant associations observed for any of the remaining 
drugs (Table 13). For UC, significant negative associations were observed for 5-ASA drugs 
in the entire and incident cohorts (p  <0.01). There was a significant negative association for 
aspirin in the incident cohort (p <0.01), but not the entire cohort. NA-antiplatelet medications 
were significantly negatively associated with IBD-CRC in the entire but not incident cohort. 
Any statin had a significant negative association in both cohorts, with an apparent dose 
response and greater association size in higher dose statin prescription in both cohorts. 
Lipophilic, but not hydrophilic statins showed a significant negative association. For UC, 
there were no significant associations for immunomodulators, or NA-NSAIDs. (Table 14)   
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Table 9 Demographics of the chemoprevention entire cohort and incident cohort. Matched cohort (1:10) 
  Entire cohort Incident (1yr) cohort 
  Controls 
Colorectal cancer 
cases  Controls 
Colorectal cancer 
cases  
    n % n % p-value n % n % p-value 
Total 1432  211   746  119   
            
IBD subtype Crohn's disease 369 25.8 58 27.5  186 24.9 31 26.1  
 Ulcerative colitis 1007 70.3 237 112.3  515 69.0 76 63.9  
 Indeterminate colitis 56 3.9 16 7.6 0.04 45 6.0 12 10.1 0.22 
           
Sex Male 822 57.4 126 59.7  417 55.9 72 60.5  
 Female 610 42.6 85 40.3 0.53 329 44.1 47 39.5 0.35 
           
Year of cancer 
diagnosis before 1993 593 41.4 70 33.2  165 22.1 13 10.9  
 1993 - 2000 130 9.1 19 9.0  53 7.1 8 6.7  
 2000 - 2007 410 28.6 62 29.4  277 37.1 50 42.0  
 2007 - 2014 299 20.9 60 28.4 0.05 251 33.6 48 40.3 0.04 
           
Age at diagnosis under 20 years 342 23.9 42 19.9  85 11.4 7 5.9  
 > 20 to 30 years 343 24.0 30 14.2  139 18.6 10 8.4  
 30 to 40 years 230 16.1 31 14.7  124 16.6 14 11.8  
 50 to 60 years 220 15.4 33 15.6  153 20.5 23 19.3  
 60 to 70 years 172 12.0 38 18.0  144 19.3 34 28.6  
 > 70 years 125 8.7 37 17.5 <0.01 101 13.5 31 26.1 <0.01 
            
IBD duration (years) 0 to 2 years 60 4.2 15 7.1  56 7.5 12 10.1  
 > 2 years to 4 years 76 5.3 18 8.5  71 9.5 14 11.8  
 > 4 years to 6 years 88 6.1 16 7.6  68 9.1 13 10.9  
 > 6 years to 8 years 86 6.0 16 7.6  65 8.7 15 12.6  
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 > 8 years to 10 years 83 5.8 16 7.6  55 7.4 12 10.1  
 > 10 years 1039 72.6 130 61.6 0.03 431 57.8 53 44.5 0.18 
            
Smoking Never smoked 689 48.1 95 45.0  338 45.3 53 44.5  
 
Smoking data 
missing 28 2.0 9 4.3  11 1.5 2 1.7  
 Ever smoked 715 49.9 107 50.7 0.09 397 53.2 64 53.8 0.98 
            
IMD income category Most affluent 357 24.9 58 27.5  185 24.8 31 26.1  
 2 238 16.6 34 16.1  120 16.1 19 16.0  
 3 295 20.6 41 19.4  138 18.5 21 17.6  
 4 215 15.0 31 14.7  123 16.5 19 16.0  
 Least affluent 327 22.8 47 22.3 0.96 180 24.1 29 24.4 1 
   
         
Charlson score ≥ 2  
No 1127 78.7 156 73.9  584 78.3 87 73.1  
Yes 305 21.3 55 26.1 0.11 162 21.7 32 26.9 0.21 
 
IBD – inflammatory bowel disease; IMD – index of multiple deprivation. 
Matching variables:  Age at diagnosis cohort in bands, IBD subtype, IBD duration in 2-year bands, comorbidity score, sex, IMD quintile, smoking status, steroid prescription 
within 90 days of diagnosis
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Table 10 Matching success rate , 1 CRC to 10 controls without CRC 
in the ResearchOne IBD database 
 
211 out of 250 cases matched.   
   
Number of successful control matches n % 
0 39 15.6 
1 22 8.8 
2 18 7.2 
3 13 5.2 
4 14 5.6 
5 14 5.6 
6 13 5.2 
7 6 2.4 
8 8 3.2 
9 6 2.4 
10 97 38.8 
 
Matching variables:  Age at diagnosis cohort in bands, IBD subtype, IBD duration in 
2-year bands, comorbidity score, sex, IMD quintile, smoking status, steroid 
prescription within 90 days of diagnosis.
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Table 11 Medication use in the Medication use in the ResearchOne chemoprevention matched cohort (10:1) 
 
 Entire cohort  Incident (1yr) cohort 
 
 Controls 
Colorectal cancer 
cases   Controls 
Colorectal cancer 
cases  
    n % yes % p-value   n % yes % p-value 
 
            
Oral 5-ASA 
No 429 30.0 119 56.4   199 26.7 75 63.0  
Yes 1003 70.0 92 43.6 <0.01  547 73.3 44 37.0 <0.01              
Immunomodulator 
No 1144 79.9 188 89.1   605 81.1 105 88.2  
Yes 288 20.1 23 10.9 <0.01  141 18.9 14 11.8 0.06              
Non-aspirin NSAID 
No 905 63.2 147 69.7   431 57.8 79 66.4  
Yes 527 36.8 64 30.3 0.07  315 42.2 40 33.6 0.08              
Aspirin 
No 1157 80.8 168 79.6   579 77.6 96 80.7  
Yes 275 19.2 43 20.4 0.69  167 22.4 23 19.3 0.45              
Non-aspirin antiplatelet 
No 1323 92.4 202 95.7   683 91.6 113 95.0  
Yes 109 7.6 9 4.3 0.08  63 8.4 6 5.0 0.20              
Any statin 
No 1049 73.3 164 77.7   521 69.8 91 76.5  
Yes 383 26.7 47 22.3 0.17  225 30.2 28 23.5 0.14              
Low dose statin * 
No 1160 92.0 172 89.6   587 91.6 95 88.0  
Yes 101 8.0 20 10.4 0.26  54 8.4 13 12.0 0.22              
High dose statin *  
No 1150 91.2 184 95.8   575 89.7 104 96.3  
Yes 111 8.8 8 4.2 0.03  66 10.3 4 3.7 0.03              
Lipophilic statin ** 
No 1060 77.6 166 81.0   528 74.8 92 80.0  
Yes 306 22.4 39 19.0 0.28  178 25.2 23 20.0 0.23              
Hydrophilic statin ** No 1355 99.2 203 99.0   699 99.0 114 99.1  
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Yes 11 0.8 2 1.0 0.80  7 1.0 1 0.9 0.90 
             
            
* Those with low and high dose statin prescribed were restricted (n = 190)        
** Those prescribed lipophilic and hydrophilic statins restricted (n = 72)         
 
NA-NSAID – non-aspirin non-steroidal anti-inflammatory drug; 5-ASA – 5-aminosalicylic acid; immunomodulators include thiopurine medications and methotrexate. 
Matching variables:  Age at diagnosis cohort in bands, IBD subtype, IBD duration in 2-year bands, comorbidity score, sex, IMD quintile, smoking status, steroid prescription 
within 90 days of diagnosis 
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Table 12 Conditional logistic regression analysis of medication use and risk of subsequent IBD-CRC in the 
ResearchOne matched cohort 
 Entire cohort †  Incident (1yr) cohort ‡ 
 
Odds Ratio 
95% Confidence Intervals 
p-value 
 
Odds Ratio 
95% Confidence Intervals 
p-value  Lower Upper  Lower Upper 
Oral 5-ASA 0.32 0.23 0.45 <0.01  0.15 0.09 0.27 <0.01 
Immunomodulator 0.49 0.31 0.79 <0.01  0.65 0.34 1.24 0.34 
Non-aspirin 
NSAID 
0.68 0.49 0.95 0.02  0.68 0.43 1.08 0.10 
Aspirin 0.72 0.48 1.08 0.11  0.40 0.22 0.72 <0.01 
Non-aspirin 
antiplatelet 
0.41 0.20 0.84 0.02  0.41 0.16 1.02 0.05 
Any statin 0.55 0.37 0.81 <0.01  0.42 0.25 0.72 <0.01 
Low dose statin 1.01 0.58 1.75 0.98  0.84 0.38 1.86 0.67 
High dose statin 0.34 1.59 0.74 <0.01  0.26 0.09 0.76 0.01 
Lipophilic statin 0.60 0.40 0.90 <0.01  0.45 0.25 0.80 <0.01 
Hydrophilic statin 0.72 0.14 3.62 0.69   0.46 0.05 4.58 0.50 
 
         
Matching 
Age at diagnosis cohort in bands, IBD subtype, IBD duration in 2-year bands, comorbidity score, sex, IMD quintile, smoking status, steroid prescription 
within 90 days of diagnosis 
Adjustment for † IBD subtype, IBD duration in 2-year cohorts, Cohort year of diagnosis, Age at diagnosis cohort in bands  
Adjustment for ‡ IBD duration in 2-year cohorts, Age at diagnosis cohort in bands     
* Anyone prescribed low and high dose drug restricted      
** Anyone prescribed lipophilic and hydrophilic statins restricted     
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Table 13 Conditional logistic regression analysis of medication use and risk of subsequent IBD-CRC in the 
ResearchOne matched cohort. Entire cohort, Crohn’s disease 
 Entire cohort †  Incident (1yr) cohort ‡ 
 
Odds Ratio 
95% Confidence Intervals 
p-value 
 
Odds Ratio 
95% Confidence Intervals 
p-value  Lower Upper  Lower Upper 
Oral 5-ASA 0.31 0.16 0.61 <0.01  0.11 0.03 0.44 <0.01 
Immunomodulator 0.28 0.11 0.75 0.01  0.27 0.55 1.36 0.11 
Non-aspirin 
NSAID 
0.34 0.16 0.73 <0.01  0.35 0.12 1.00 0.05 
Aspirin 1.08 0.44 2.68 0.87  0.44 0.11 1.72 0.24 
Non-aspirin 
antiplatelet 
1.15 0.31 4.34 0.83  0.63 0.11 3.51 0.60 
Any statin 0.68 0.26 1.75 0.42  0.52 0.15 1.76 0.29 
Low dose statin 1.44 0.40 5.17 0.58  1.35 0.28 6.45 0.70 
High dose statin 0.54 0.11 2.67 0.45  0.39 0.04 4.15 0.44 
Lipophilic statin 0.94 0.36 2.44 0.91  0.83 0.24 2.85 0.76 
Hydrophilic statin                   
 
         
Matching 
Age at diagnosis cohort in bands, IBD subtype, IBD duration in 2-year bands, comorbidity score, sex, IMD quintile, smoking status, steroid prescription 
within 90 days of diagnosis 
Adjustment for † IBD subtype, IBD duration in 2-year cohorts, Cohort year of diagnosis, Age at diagnosis cohort in bands  
Adjustment for ‡ IBD duration in 2-year cohorts, Age at diagnosis cohort in bands    
* Anyone prescribed low and high dose drug restricted      
** Anyone prescribed lipophilic and hydrophilic statins restricted     
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Table 14 Conditional logistic regression analysis of medication use and risk of subsequent IBD-CRC in the 
ResearchOne matched cohort. Entire cohort, Ulcerative colitis 
 Entire cohort †  Incident (1yr) cohort ‡ 
 
Odds Ratio 
95% Confidence Intervals 
p-value 
 
Odds Ratio 
95% Confidence Intervals 
p-value  Lower Upper  Lower Upper 
Oral 5-ASA 0.34 0.23 0.51 <0.01  0.17 0.88 0.31 <0.01 
Immunomodulator 0.67 0.38 1.15 0.15  0.99 0.48 2.07 0.99 
Non-aspirin NSAID 0.83 0.56 1.25 0.38  0.82 0.47 1.41 0.47 
Aspirin 0.71 0.44 1.16 0.17  0.42 0.21 0.84 0.01 
Non-aspirin antiplatelet 0.28 0.10 0.80 0.02  0.34 0.10 1.19 0.09 
Any statin 0.58 0.37 0.91 0.02  0.42 0.22 0.79 0.01 
Low dose statin 0.96 0.5 1.84 0.91  0.75 0.28 2.00 0.57 
High dose statin 0.39 0.16 0.96 0.04  0.34 0.1 1.19 0.09 
Lipophilic statin 0.63 0.39 1.01 0.06  0.47 0.24 0.92 0.03 
Hydrophilic statin 0.62 0.07 5.59 0.67           
 
         
Matching 
Age at diagnosis cohort in bands, IBD subtype, IBD duration in 2-year bands, comorbidity score, sex, IMD quintile, smoking status, steroid 
prescription within 90 days of diagnosis 
Adjustment for † IBD subtype, IBD duration in 2-year cohorts, Cohort year of diagnosis, Age at diagnosis cohort in bands  
Adjustment for ‡ IBD duration in 2-year cohorts, Age at diagnosis cohort in bands    
* Anyone prescribed low and high dose drug restricted      
** Anyone prescribed lipophilic and hydrophilic statins restricted     
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7.3.3 Adverse outcomes 
I performed a series of nested case control analysis to compare adverse 
outcomes of independent steroid prescriptions, and surgery or immunomodulator 
prescription at least one year after being prescribed each medication. I used a 
matched analysis, 1 control for every case of CRC. Matching variables were age at 
diagnosis in cohorts, IBD subtype, co-morbidity score, gender, deprivation score, 
smoking status, and whether steroids were prescribed within a year of diagnosis. The 
case and control groups were balanced after matching with no significant differences 
for any of the matching variables. 
Being prescribed a NA-NSAID medication was significantly associated with 
an increase in the number of independent steroid prescriptions (OR 1.28, 95% CI 
1.18 to 1.39). Being prescribed aspirin (OR 0.87, 95% CI 0.78 to 0.96), or a statin 
(OR 0.65, 95% CI 0.59 to 0.71) was associated with a reduction in the number of 
independent steroid prescriptions. (Table 15) 
Being prescribed aspirin was associated with lower odds of undergoing a 
surgical resection one year after IBD diagnosis (OR 0.53, 95% CI 0.40 to 0.71), as 
was being prescribed a statin (OR 0.44, 95% CI 0.34 to 0.57). NA-NSAIDS had no 
association (OR 0.87, 95% CI 0.73 to 1.04). (Table 16) 
Being prescribed aspirin (OR 0.57, 95% CI 0.46 to 0.71), or statin 
medication (OR 0.78, 95% CI 0.66 to 0.93), was significantly associated with a 
reduced odds of being prescribed an immunomodulator medication with one year of 
IBD diagnosis. Being prescribed a NA-NSAID medication had no association (OR 
0.98, 95% CI 0.86 to 1.12). (Table 17) 
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Table 15 Odds of increasing number of independent steroid prescriptions depending on prior prescription of NA-
NSAIDs, aspirin, or statin medication. Matched 1 case with 1 control. 
 Entire cohort Incident cohort 
 
Odds Ratio 
95% Confidence 
Intervals 
p-value Odds Ratio 
95% Confidence 
Intervals 
p-value 
  Lower Upper Lower Upper 
NA-NSAID 1.31 1.17 1.46 <0.01 1.53 1.37 1.7 <0.01 
Aspirin 1 0.86 1.17 0.97 0.89 0.72 1.11 0.3 
Statin 0.63 0.58 0.68 <0.01 0.63 0.57 0.7 <0.01 
 
NA-NSAID – non-aspirin non-steroidal anti-inflammatory drug. 
Matching variables: age at diagnosis in cohorts, IBD subtype, co-morbidity score, gender, deprivation score, smoking status, and whether steroids were prescribed within a year 
of diagnosis. 
Groups balanced, with no statistical differences after matching.
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Table 16 Odds of surgical resection at least 1 year after being prescribed a given medication. Matched 1 case with 
1 control. 
 Entire cohort Incident cohort 
 
Odds Ratio 
95% Confidence 
Intervals 
p-value Odds Ratio 
95% Confidence 
Intervals 
p-value 
  Lower Upper Lower Upper 
NA-NSAID 0.87 0.73 1.04 0.13 1.96 1.47 2.61 <0.01 
Aspirin 0.53 0.4 0.71 <0.01 0.89 0.58 1.36 0.58 
Statin 0.44 0.34 0.57 <0.01 1 0.67 1.48 1 
NA-NSAID – non-aspirin non-steroidal anti-inflammatory drug. 
Matching variables: age at diagnosis in cohorts, IBD subtype, co-morbidity score, gender, deprivation score, smoking status, and whether steroids were prescribed within a year 
of diagnosis. 
Groups balanced, with no statistical differences after matching
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Table 17 Odds of being prescribed an immunomodulator medication at least 1 year after being prescribed a given 
medication. Matched 1 case with 1 control. 
 Entire cohort Incident cohort 
 
Odds Ratio 
95% Confidence 
Intervals 
p-value Odds Ratio 
95% Confidence 
Intervals 
p-value 
  Lower Upper Lower Upper 
NA-NSAID 0.98 0.86 1.12 0.82 1.07 0.88 1.3 0.52 
Aspirin 0.57 0.46 0.71 <0.01 0.76 0.56 1.03 0.08 
Statin 0.78 0.66 0.93 <0.01 0.76 0.6 0.98 0.03 
NA-NSAID – non-aspirin non-steroidal anti-inflammatory drug. 
Matching variables: age at diagnosis in cohorts, IBD subtype, co-morbidity score, gender, deprivation score, smoking status, and whether steroids were prescribed within a year 
of diagnosis 
Groups balanced, with no statistical differences after matching
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7.4 Discussion 
In this analysis of over 16,000 individuals I have shown that regular use of 5-ASA 
drugs is consistently negatively associated with IBD-CRC. Statins showed a similar negative 
association, particularly lipophilic statins and there was an apparent dose response with high 
dose statins showing a greater negative association with IBD-CRC.   Further, in the adverse 
events analysis statin or aspirin prescriptions were associated with fewer adverse events.  
5-ASA is the most used medication for the treatment of UC and is frequently used in 
colonic CD. There has been considerable interest in 5-ASA as a chemoprophylactic drug in 
IBD following publication of observational epidemiological data from case control series 
suggested that regular 5-ASA use reduce the risk of IBD-CRC. (Eaden et al., 2000) There is 
substantial biological plausibility for this role, as 5-ASA has been demonstrated in pre-
clinical models of carcinogenesis to suppress several of the hallmarks of cancer: sustaining 
proliferative signalling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, and activating invasion and metastasis. (Hanahan and 
Weinberg, 2011)  5-ASA can induce cell cycle arrest in multiple CRC cell lines, antagonise 
β-catenin signalling (which is dysregulated in majority of CRC), suppress the COX-2/PGE2 
axis, potentiate PPARγ signalling with subsequent upregulation of tumour suppressor PTEN 
and enhance replication fidelity. (Stolfi et al., 2013) There has been conflicting observational 
evidence between population-based and referral populations for its potential role in the 
chemoprevention if IBD-CRC. In a meta-analysis of population based, non-referral centre 
studies incorporating four studies (608 CRC cases and 2177 controls), 5-ASA use was not 
associated with a reduced incidence of IBD-CRC (OR 0.95, 95% CI 0.66 to 1.38). (Nguyen, 
Gulamhusein and Bernstein, 2012)  However, two recent meta-analyses have provided 
further evidence for the chemoprophylactic properties of 5-ASA for IBD-CRC. In their 2016 
meta-analysis of 9 population based and 17 referral centre based studies, involving 1958 
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IBD-CRC cases and 13492 controls, Qiu et al found a protective effect of 5-ASA against 
IBD-CRC (OR 0.58, 95% CI 0.45 – 0.75). (Qiu et al., 2016) Interestingly, whilst the effect 
was lost in the analysis of population-based studies, a protective effect was demonstrated for 
patients with UC (OR 0.23, 95% CI 0.09 – 0.6) but not for patients with CD (OR 0.37, 95% 
CI 0.12 – 1.14); 5-ASA was not shown to reduce risk of IBD-CRC for patients with CD, 
neither in the population-based or referral centre-based analyses, although a pooled analysis 
did demonstrate a protective benefit if a trial reporting neoplasia as CRC or dysplasia was 
excluded (OR 0.48, 95% CI 0.26 – 0.88). A further meta-analysis by Bonovas et al of 5-ASA 
and IBD-CRC involving 2,137 cases of IBD-CRC across 31 studies (12 population-based, 19 
referral-centre based) reported an overall risk reduction of CRC or dysplasia of 43% (RR 
0.57, 95% CI). (Bonovas et al., 2017) They found the inverse relationship between 5-ASA 
use and IBD-CRC was significant amount both population-based (RR 0.70, 95% CI 0.52 – 
0.94) and referral-centre studies (RR 0.46, 95% CI  0.34 – 0.61). Interestingly, whilst 5-ASA 
was protective for patients with UC, the risk reduction in patients with CD was weaker and 
non-significant (RR 0.76, 95% CI 0.43 – 1.33). In my results there was a similar protective 
association for both CD and UC IBD subtypes with prescription of oral 5-ASA medications.  
Here, with data taken exclusively from a primary care population, it provides further 
evidence that 5-ASA has chemoprophylactic properties against IBD-CRC. Current guidelines 
from the European Crohn’s and Colitis Organisation, recommend that 5-ASA medications 
should be considered for all those with UC (Magro et al., 2017) because of their potential 
chemopreventative effects although this strategy is yet to be endorsed by other societal 
guidelines.  
The inverse association between high-dose statin use and IBD-CRC is consistent with 
previous cohort studies, Anathakrishnan and colleagues, analysing a cohort of >11,000 IBD 
patients reported age-adjusted OR of 0.35 (0.24 – 0.53). The antineoplastic mechanisms 
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underpinning this association are not fully understood but are likely to, at least in part, be the 
result of inhibition of the mevalonate biosynthetic pathway and subsequent suppression of 
downstream mediators including isoprenoids. Depletion of isoprenoids is associated with 
enhanced apoptosis, inhibition of cellular proliferation and inhibition of angiogenesis in 
models of tumorigenesis. (Bardou, Barkun and Martel, 2010) Isoprenoids are required for 
post-translational modification of small GTPases including Ras, which is commonly mutated 
in tumours. Ras is dependent on prenylation for its membranous translocation and subsequent 
signalling activity. Accordingly, in preclinical models of cancer, atorvastatin has been shown 
to decrease membrane-bound Ras. (Beckwitt, Shiraha and Wells, 2018) 
Lipophilic statins (at any dose) but not hydrophilic statins (at any dose) were 
associated with an inverse risk of IBD-CRC, with in pooled cases of IBD and UC alone, 
albeit a borderline association in the entire cohort. Similar findings for chemoprevention 
depending on statin lipophilicity have been observed in a Swedish cohort of patients with 
chronic viral hepatitis: lipophilic statin use but not hydrophilic statin use was associated with 
a significant reduction in hepatocellular carcinoma cases. (Simon et al., 2019) Beckwitt and 
colleagues reported that lipophilicity of statins was directly related to efficacy in suppressing 
tumour cell growth in preclinical models of breast, prostate, brain and melanoma tumours, 
(Beckwitt, Shiraha and Wells, 2018) replicating data from pancreatic cell lines. (Hao et al., 
2019) Further, using the azoxymethane/dextran sodium sulphate (AOM/DSS) murine model 
of colitis-induced colorectal cancer, Yasui and colleagues demonstrated that the lipophilic 
statin pitavastatin suppressed the number of neoplastic lesions through activation of apoptosis 
and modulation of mucosal inflammation, oxidative stress and cellular proliferation. (Yasui et 
al.) It is uncertain whether statins have a different effect depending on the colonic location of 
the tumour. Unfortunately, tumour site was not available in this dataset and so this question 
was beyond the realm of this study. In a large cohort study examining the relationship 
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between statin use and risk of sporadic post-colonoscopy CRC, Cheung and colleagues 
demonstrated in their stratified analysis that statin use was associated with a lower risk of 
PCCRC in the proximal colon, but not the distal colon. (Cheung et al., 2019) This raises the 
possibility that statins may exert more of an effect on tumours arising from the serrated 
pathway which are more commonly found in the proximal colon. (Lytras, Nikolopoulos and 
Bonovas, 2014) IBD-CRC is also found more commonly in the proximal colon but at present 
this potential mechanism is not clear, particularly as IBD-CRC tumours are biologically 
different to those arising from the serrated pathway. These questions should be addressed in 
future studies. 
Here, the adverse outcome analysis demonstrated that statins are associated with 
improved outcomes for those with IBD with reduced numbers of independent steroid 
prescriptions, reduced surgery, and reduced prescriptions of immunomodulator medications 
within a year of starting a statin. There are conflicting observational clinical data on the 
potential association between statins and IBD outcomes.  However, there is a growing body 
of preclinical data that suggests that statins may have beneficial immunomodulatory effects in 
several conditions including IBD by modulating antigen presenting function of immune cells, 
T-lymphocyte function, inflammatory cell migration and effects on nitric oxide. (Côté-
Daigneault et al., 2016) Experimental work has shown that atorvastatin promoted the 
expansion of myeloid derived suppressor cells, and supressed T-cell response by nitric oxide 
production both in vivo and in vitro. (Lei et al., 2016) Data from animal models, including 
AOM/DSS and trinitrobenzene sulfonic acid murine models of colitis, have shown that 
statins mediate intestinal cytokine/chemokine profile, decrease lymphocyte adhesion, modify 
intestinal flora and may have a role in fibrosis. (Côté-Daigneault et al., 2016) A further study 
showed that the addition of atorvastatin attenuated 2,4,6-trinitrobeneze sulfonic acid (TNBS)-
induced colitis in mice. (Rashidian et al., 2016) 
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To date, clinical data aimed at determining impact of statin on IBD outcomes has 
yielded mixed results, mainly based on retrospective observational data with no 
comprehensive prospective trials, systemic reviews or meta-analyses to my knowledge. One 
retrospective study showed that statin users had reduced need for steroids and anti-TNF-α 
medication and had improved outcomes. (Crockett et al., 2012) There is conflicting 
observational evidence that statin use may protect against the onset of IBD. (Ungaro et al., 
2014; Khalil et al., 2015) In a retrospective case-control study from the USA, statin use was 
significantly negatively associated with pouch related complications and antibiotic use in 
those with a J-pouch and ileo-anal anastomosis. (Kaimakliotis et al., 2017) To date there is 
not a large body of evidence and there are yet to be any comprehensive prospective studies. A 
small single arm study of ten patients with CD showed that the use of atorvastatin reduced 
inflammatory markers in those with CD. (Grip, Janciauskiene and Bredberg, 2008) However, 
An Indian RCT of low dose atorvastatin therapy (20mg) versus placebo, was associated with 
worse clinical outcomes in mild to moderate UC. (Dhamija et al., 2014)  
The possible protective association with statins and IBD-CRC, and association with 
fewer negative outcomes raises the possibility of a dual purpose for these medications in IBD 
management. Furthermore, IBD is associated with an increased risk of coronary artery 
disease.  (Bernstein, Wajda and Blanchard, 2008) This seems to be largely driven by a 
chronic inflammatory state as there is increasing evidence that acute phase proteins, such as 
C-reactive protein (CRP) are important risk factors for coronary artery disease. CRP deposits 
in the artery wall during atheromatous plaque formation and promotes low density lipoprotein 
uptake. (Zwaka, Hombach and Torzewski, 2001) Traditional risk factors for coronary artery 
disease such as hyperlipidaemia, smoking, obesity and type 2 diabetes are not consistently 
associated with coronary artery disease in the IBD population.  (Gandhi et al., 2012) 
Controlling luminal inflammation, therefore, seems important not just for reducing direct 
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consequences from bowel injury and inflammation, but also protecting against cardiovascular 
morbidity and early mortality.  
I did not demonstrate a consistent negative association with aspirin use and the 
prevention of IBD-CRC. There was a significant negative association in the incident cohort 
for all IBD combined UC, but no association in the other subgroups. Aspirin has plausible 
biological mechanisms for preventing carcinogenesis, many of which are shared with 5-ASA 
(Stolfi et al., 2013) and there is substantial epidemiological evidence that aspirin use is 
associated with reduced risk of multiple primary cancers including sporadic CRC. (Rothwell 
et al., 2010a) Prospective RCTs have reported that high-dose aspirin reduces polyp burden in 
individuals with the familial cancer syndrome familial adenomatous polyposis (Burn et al., 
2011a) and halved the incidence of CRC in patients with Lynch syndrome. (Burn et al., 
2011b) Aspirin may have no effect on IBD-CRC but there could be other explanations for the 
absence of an association seen here. Aspirin use is available over the counter in the UK, so it 
is possible that not all aspirin use was be captured by this study, with some of the controls 
potentially taking the medication. This would dilute any association. Secondly, aspirin use 
has been shown to have potential negative effects on the GI tract, including GI bleeding, so it 
is plausible that its use is discouraged by physicians managing those with IBD. I would not 
necessarily expect a difference between cases and controls, but low use in this IBD cohort 
may mean that this study was underpowered to detect a difference. It is speculative, but 
plausible, those with the longest disease duration, and most severe disease may have more 
encounters with secondary care physicians where they may be more likely to be advised not 
to take aspirin or NA-NSAID medications. Lastly, the chemoprophylactic effects of aspirin is 
dose dependent, much in the same way that the chemoprophylactic benefit of 5-ASA is seen 
at doses >1.2g/day, (Qiu et al., 2016; Bonovas et al., 2017) with benefits seen at doses > 
100mg/day. (Rothwell et al., 2010a) Given that most prescriptions for aspirin in the UK are 
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for secondary prevention of cardiovascular disease at 75mg daily, this dose may be 
insufficient to confer a chemoprophylactic benefit. I did not have a sufficient number of 
patients taking regular aspirin at more than 75mg per day to explore this. The potential 
association for aspirin does warrant further investigation but may need more detailed clinical 
note reviews than is possible with population-based primary care data. 
My meta-analysis did not find a significant association with aspirin or NA-NSAIDs. 
(Burr, Hull and Subramanian, 2016a) A recent network meta-analysis investigated the 
association of 14 potential chemopreventative medications in high risk individuals, with a 
previous history of colorectal cancer in a non-IBD population. (Dulai et al., 2016) Network 
meta-analysis allows the ranking of medications, estimating the chance that a particular 
treatment is “best”. (Salanti, Ades and Ioannidis, 2011)  NA-NSAIDs (OR 0.37, 95% credible 
interval 0.24 to 0.53), and aspirin (OR 0.71, 95% credible intervals 0.41 to 1.23) were 
significantly better than placebo with NA-NSAIDs being ranked the highest.  
There was more consistent evidence found for non-aspirin antiplatelet medications. 
Significant negative associations were observed in both cohorts for all IBD cases, and the 
entire cohort for UC with a trend towards significance in the incident cohort for UC.  There 
was  no association seen for CD alone. Antiplatelets may have a role in CRC 
chemoprevention through modifying the tumour microenvironment. Activated platelets 
release inflammatory mediators, growth factors, and angiogenic factors which may be 
associated with increased risk of CRC. (Patrignani and Patrono, 2016) There is also some 
evidence that platelets can alter the host local immune response to CRC, which may facilitate 
cancer growth and metastatic potential. (Contursi et al., 2017; Xu, Yousef and Ni, 2018) 
There is some observational data that antiplatelets may have a role in preventing sporadic 
CRC. A study of over 15,000 CRC cases and 60,000 controls showed a 20% reduction in 
CRC associated with clopidogrel prescription (OR 0.8; 95% CI 0.69 to 0.93). (Rodríguez-
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Miguel et al., 2018)  There is a lack of data for IBD-CRC, but the results shown here taken 
together with the laboratory data, and observational data with sporadic CRC show that this 
may be another option for chemoprevention. Again, more work is needed. 
Strengths and weaknesses 
I included a large sample size of over 16,000 individuals in our entire cohort and 
10,000 in our incident cohort. In the nested case control analyses, IBD duration was 9 years 
and 7 years in our entire cohort and incident cohort respectively. This should be a reasonable 
time to expect any chemopreventative association to be detected and a long enough follow up 
for adverse events to occur.  
A strength of this study is that the study cohort is likely to be representative of the full 
clinical spectrum of IBD as over 98% of UK residents are registered with a GP. (Herrett et 
al., 2010) Previous studies have shown that Read code entries were >90% accurate in an 
analysis of IBD in a similar UK primary care database, the General Practice Research 
Datalink (now called the Clinical Practice Research Datalink). (Lewis et al., 2002)  
Furthermore, the ResearchOne database has now been validated with IBD diagnoses recorded 
in 98% of cases. (Burr et al., 2018a) Studies using secondary or tertiary care data are likely to 
have an inherent referral bias, typically including those with more severe disease, which is 
relevant because risk of IBD-CRC is proportional to extent and severity of disease. (Rutter et 
al., 2004a) I was able to include several variables in the matching model that are associated 
with CRC, including: co-morbidity, social deprivation, gender, age at diagnosis, duration of 
disease, and smoking history. A further strength is that aspirin, statins and antiplatelet 
medications are typically prescribed for chronic diseases and so I would not routinely expect 
these to be discontinued. 
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There are limitations to this study. The results relate to the prescription of drugs and I 
do not know whether these prescriptions were obtained or taken as instructed. However, non-
adherence would weaken any associations.   
 Drug use may be the cause or the effect of potential residual confounding factors. 
There may be uncontrolled variables which may be responsible for an association bias. Risk 
factors for sporadic CRC not controlled for include family history, history of polyposis 
syndromes, and acromegaly. I was also unable to correct for obesity as body mass index 
measurement is not recorded consistently and may relate to CRC. Future studies should 
record such anthropometric information. The matched, nested case control design allows 
correction for known confounders for IBD-CRC that were available in the ResearchOne 
dataset. This design can introduce bias as the matching process could create a sample of 
controls that matches the cases but is not representative of the IBD population as a whole. 
This would shift the drug exposure frequency toward that in the cases and dilute any 
association found. This bias is a consideration here, as I was unable to find a suitable matched 
control for 29 cases of CRC. Results from the study are therefore only generalisable to those 
included in the study.  
I used a dichotomous exposure of ever and never having been prescribed each drug 
and did not have information on duration and cumulative dose exposure. Demonstrating dose 
and time-response effects would help support a causal relationship and suggest if any of these 
drugs could be used as chemoprevention in high-risk groups. I did not have phenotypic data 
on disease extent and the use of anti-TNFα medication which is typically used in more severe 
disease and may be a potential confounder. It is administered from hospital specialists, so 
prescribing data is not consistently available in primary care databases. However, widespread 
use for maintenance therapy was not adopted in the UK until 2010 (NICE. Guidance and 
guidelines., 2010) and between 2002 and 2010 episodic treatment was available but uptake 
- 131  
was low.  Less than 3% of those with IBD in the UK were prescribed an anti-TNFα in 2010. 
(Bardhan et al., 2010) In the UK immunomodulator drugs are typically commenced from 
secondary care clinics with monitoring for any potential intolerance or adverse side effects. 
(Lamb, 2019) The medications are then usually continued through primary care prescriptions 
and so will be captured in ResearchOne. The analyses could also be subject to multiple 
analyses bias where significant associations will be observed by chance alone. I used a 
restrictive p-value of  <0.01 as a level of significance which will limit this potential bias but 
for all the analyses this bias should be considered, and results be taken as association and not 
causal for reduction in IBD-CRC.  
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7.5 Conclusions 
In summary, I report an inverse association between regular use of 5 -ASA drugs and 
statins in the development of IBD-CRC. As there is biological plausibility for a 
chemoprotective effect of these medications, further aetiological studies are required to 
determine whether the associations are consistent and hence likely to be causal. If this inverse 
association is consistent then investigation of these medications as potential 
chemopreventative agents for those at high risk of developing IBD-CRC in clinical trials 
would be justified. Furthermore, this work has shown that aspirin and statins may have a role 
in controlling disease activity and reducing the steroid prescriptions.  
The use of statins in an anti-inflammatory and anti-neoplastic role is attractive as they 
are cheap, with a good safety profile and may confer additional health benefits. My results 
add weight to this, and there is justification for targeted clinical trials, for primary prevention 
or as an adjunct to conventional oncological treatments. 
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Chapter 8 Discussion 
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Chapter 8: Discussion 
IBD is a common disease with population prevalence estimates at ~0.4% in the West. 
(Molodecky et al., 2012) It is life-long, with onset in early age, and is associated with excess 
morbidity and early mortality. One of the most serious complications is CRC. As with any 
disease prevention is better than cure and it is important to determine whether routinely 
prescribed medications, that are safe and well tolerated, have a role. 
This work has shown that there is the potential for routinely prescribed medications to 
prevent IBD-CRC. In Chapter 4, a systematic review of the existing literature and meta-
analysis has shown that folate may have a role. (Burr, Hull and Subramanian, 2016b) In 
Chapter 7, promising associations are seen for several routinely prescribed medications 
including: 5-ASA medications, high-dose statins, lipophilic statins and potentially non-
aspirin antiplatelet medications. Importantly, statins were also associated with less 
independent steroid prescriptions, that when calculated in a similar way, has a positive 
predictive value of 85% for predicting a flare of IBD in a prior validation study. (Lewis et al., 
2004) I have replicated findings from review of the existing literature in Chapter 3, that 
aspirin, or NA-NSAIDs do not appear to have a chemopreventative effect in IBD-CRC as 
they do in sporadic CRC. Thiopurine medications show no association although results from 
observational data, including here, should be taken with caution as these studies have 
inherent bias and are likely to be confounded by indication. Those with the most severe 
disease, and greater risk of CRC are also more likely to be prescribed a thiopurine. 
An important finding is that the data held within ResearchOne is accurate when 
compared to a gold-standard of a multitude of hospital record sources. Primary care databases 
are a rich resource of healthcare data and are extremely useful for exploring rare, or long-
term outcomes where prospective studies are not feasible. Confidence is required in the data 
before applying any results to clinical practice or when planning randomised trials. Whilst 
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other resources have been validated, this is the first study using ResearchOne data. Results 
were consistent with prior reports from other data sources and validation methods. This 
should give confidence in using the ResearchOne database for epidemiological and 
aetiological studies, particularly those in IBD. 
Performing detailed studies such as these is important in the understanding of the 
natural history of diseases. Large-scale, accurate, population-based datasets such as 
ResearchOne provide a valuable research resource for these goals. Here I have shown that the 
proportion of those with IBD developing CRC is significantly increasing. I have also 
confirmed established risk factors for the disease including male gender, duration of disease, 
comorbidity, and immunomodulator use which is likely to be a proxy marker for more 
advanced disease with more mucosal inflammation. Establishing these risk factors is 
important when developing guidelines for screening and surveillance of this population to 
utilise scarce resources most appropriately and not expose people to potentially unnecessary 
investigations that are not without risk. 
I have also confirmed that whilst duration of disease is important, there are also a 
large number of people who develop cancer before the recommended start date for screening 
and future surveillance at eight to ten years. This is important to consider in future guidelines.   
8.1 Future research targets 
There is a need to further explore the negative associations demonstrated here, with 
high-dose and lipophilic statins and IBD-CRC. The first step would be to perform a 
systematic review and meta-analysis of the available evidence, incorporating the results from 
this study. To my knowledge there are only a small number of studies investigating the 
potential role of statin medication as potential chemopreventative agents. These have been 
conflicting, but with the addition of the results here there may be enough data to explore this 
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association further. This would define any association more precisely and could form the 
basis for a prospective randomised investigation.  
Inflammation is one of the most important aetiological factors in IBD-CRC, and 
perhaps the only modifiable risk factor. There have been significant advances in the treatment 
options to promote mucosal healing, and histological remission is now the endpoint in some 
new treatment trials. (Darr and Khan, 2017) Plausibly, this should reduce the potential for 
malignant transformation. (Saxena, Limdi and Farraye, 2017) To date, there is scant research 
investigating any association with biological and small molecule drugs and the development 
of IBD-CRC. Large cohorts, including registry data could be used to explore these outcomes, 
particularly anti-TNFα medications which have now been widely used since 2010 and should 
have had enough time to exert a potential chemopreventative effect. These investigations are 
important. The use of biological and small molecule drugs is likely to reduce the use of 
surgery to cure aggressive, longstanding disease. Colonic surgery obviously reduces the 
potential for developing colon cancer. These individuals are likely to be at a higher inherent 
risk of cancer with the most aggressive disease. Defining a negative association would add 
weight to the goal of mucosal healing, over clinical remission as proposed by some 
jurisdictions. (Darr and Khan, 2017) Chemoprevention of colorectal cancer in IBD might be 
added as an extra benefit of pursuing this goal.  A potential first target for prospective studies 
would be high-risk cohorts, such as those with co-existent PSC, previous low-grade dysplasia 
or a strong family history of sporadic CRC. 
In summary, there is hope for the chemoprevention of IBD-CRC and 5-ASA drugs 
statins, and folate supplementation are attractive targets. There have been many new 
additions to the therapeutic armamentarium for colonic IBD in recent years including new 
biological medications such as anti-integrin and janus kinase inhibitors. Luminal 
inflammation is one of the strongest risk factors for the development of IBD-CRC. There is 
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additional hope that with improved control of disease activity the burden of this important 
disease may be reduced. There are also further advancements with detection through high 
definition chromoendoscopy and the ability to resect cancerous and pre-cancerous lesions 
through endoscopic mucosal resection and dissection so the model may move to preventative 
colonoscopy removing cancerous precursors similarly to the reduction of sporadic CRC by 
the judicious removal of adenomatous polyps. 
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5-ASA 5-aminosalicylic acid 
AOM/DSS Azoxymethane/dextran sodium sulphate  
APC adenomatosis polyposis coli 
BNF British National Formulary  
BSG British society of Gastroenterology 
CD Crohn's disease 
CI Confidence interval 
COX  Cyclo-oxygenase  
COX-2 Cyclo-oxygenase-2  
CPRD Clinical Practice Research Datalink  
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GP General practitioner 
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HMG-Co-A 3-hydroxy-3methylglutaryl-coenzyme-A reductase inhibitors  
HR  Hazards ratio 
IBD Inflammatory bowel diseases 
IBD-CRC Inflammatory bowel disease associated colorectal cancer 
IBD-U IBD unclassified 
IMD Index of Multiple Deprivation  
IPF-4 Intracellular platelet factor 4  
MeSH Medical subject heading 
MOOSE Meta-analysis of Observational Studies in Epidemiology 
NA-NSAIDs Non-aspirin non-steroidal anti-inflammatory drugs 
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NOS Newcastle Ottowa scale 
NSAID Non-steroidal anti-inflammatory drug 
OP Outpatient 
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TGF-β Transforming growth factor beta  
THIN The Heath Improvement Network  
TNBS Trinitrobenzene sulfonic acid  
TNFα Tumour necrosis factor alpha 
UC Ulcerative colitis 
UK  United Kingdom 
USA United states of America 
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Appendices 
 
Appendix 1 Read codes (CTV3) for inflammatory bowel diseases used in 
the study 
Read code (CTV3) Description Study definition 
J40.. Regional enteritis - Crohn's disease Crohn's disease 
J4002 Crohn's disease of terminal ileum Crohn's disease 
J4003 Crohn's disease of the ileum unspecified Crohn's disease 
J4004 Crohn's disease of the ileum NOS Crohn's disease 
J4010 Crohn's colitis Crohn's disease 
J4011 Crohn's proctitis Crohn's disease 
J401z Crohn's disease of the large bowel NOS Crohn's disease 
Jyu40 [X]Other Crohn's disease Crohn's disease 
X302t Crohn's ileitis Crohn's disease 
XaK6D Exacerbation of Crohn's disease of large intestine Crohn's disease 
XE0af Crohn's disease of the large bowel NOS Crohn's disease 
XE2QL Crohn's disease Crohn's disease 
J410. Ulcerative colitis confined to rectum and sigmoid colon Ulcerative colitis 
J4100 Ulcerative ileocolitis Ulcerative colitis 
J4102 Ulcerative rectosigmoiditis Ulcerative colitis 
J4103 Ulcerative colitis confined to rectum Ulcerative colitis 
J410z Ulcerative proctocolitis NOS Ulcerative colitis 
Jyu41 [X]Other ulcerative colitis Ulcerative colitis 
XaK6E Exacerbation of ulcerative colitis Ulcerative colitis 
XaYzX Ulcerative pancolitis Ulcerative colitis 
XaZ2j Left sided ulcerative colitis Ulcerative colitis 
XE0ag Ulcerative colitis Ulcerative colitis 
X303k Indeterminate colitis Indeterminate colitis 
XE0ae Inflammatory bowel disease Indeterminate colitis 
 
Appendix 2 Read code definitions for colorectal cancer 
Read code CTV3 code Definition 
9C52. Malignant neoplasm rectum, rectosigmoid junction and anus NOS 
B11y. Malignant neoplasm of caecum (& carcinoma) 
B120. Malignant neoplasm of splenic flexure of colon 
B13.. Malignant tumour of colon 
B130. Malignant neoplasm of ascending colon 
B131. Malignant tumour of transverse colon 
B132. Malignant neoplasm of sigmoid colon 
B133. Malignant neoplasm of colon NOS 
B134. Malig neop other site rectum, rectosigmoid junction and anus 
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B136. Malignant tumour of ascending colon 
B13z. Malignant neoplasm of colon (& NOS) 
B14.. Malignant neoplasm of other specified sites of colon 
B140. Malignant tumour of rectosigmoid junction 
B141. Malignant neoplasm of rectum (& carcinoma) 
B142. Malignant neoplasm of hepatic flexure of colon 
B143. Malignant neoplasm of transverse colon 
B803. Carcinoma in situ of colon 
B8031 Carcinoma in situ of transverse colon 
B8033 Carcinoma in situ of sigmoid colon 
B803z Carcinoma in situ of colon NOS 
B804. Carcinoma in situ of rectum and rectosigmoid junction 
B8041 Carcinoma in situ of rectum 
X78gK Malignant tumour of intestine 
X78gM Carcinoma of caecum 
X78gN Malignant tumour of large intestine 
X78gO Adenocarcinoma of colon 
X78Nj Tumour of caecum 
X78Np Tumour of colon 
X78Nu Tumour of hepatic flexure 
X78OA Tumour of sigmoid colon 
X78OE Tumour of rectosigmoid junction 
X78OI Tumour of rectum 
X78OK Adenocarcinoma of rectum 
Xa34H Carcinoma of sigmoid colon 
Xa84V Adenocarcinoma of sigmoid colon 
XaDc5 Carcinoma of ascending colon 
XaDc6 Carcinoma of transverse colon 
XaDc7 Carcinoma of descending colon 
XaDc8 Carcinoma of hepatic flexure 
XaFrJ Local recurrence of malignant tumour of rectum 
XaFro Metastasis from malignant tumour of colon 
XE1vU Malignant tumour of caecum 
XE1vV Malignant neoplasm of colon NOS 
XE1vW Malignant tumour of rectum 
XE1xd Ca colon NOS 
XE1xh Carcinoma of the rectosigmoid junction 
XE1xj (Ca rectum) or (rectum carcinoma) 
XE1xL Carcinoma of colon 
XE1xT Ca sigmoid colon 
XE1xX Ca ascending colon 
 
Appendix 3 Read code definitions for gastrointestinal surgery 
 
Read code (CTV3) Surgery definition 
77210 Abdominoperineal excn rectum & end colostomy (& named vars) 
Y21ld Abdominoperineal resection 
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YMGtu Abdominoperineal resection 
Y21lY Abdominoperineal resection rectum 
XaDto Ant resect rectum stapled anast sigmoid to anus with J pouch 
77213 Anterior resection of rectum and anastomosis NEC 
77214 Anterior resection of rectum and exteriorisation of bowel 
XaFza Anterior resection of rectum with anastomosis 
77212 Anterior resection rectum + staple anastomosis colon-rectum 
Y21lf AP resection 
Y21le AP resection of rectum 
7642 Bypass of ileum 
7642z Bypass of ileum NOS 
X20X5 Caecal operation 
76483 Closure of perforation of ileum 
76352 Closure of perforation of jejunum 
X20XD Colectomy 
77172 Colectomy and anastomosis NEC 
77170 Colectomy and end-to-end anastomosis of colon to colon NEC 
XE0DC Colectomy and exteriorisation of bowel NEC 
77173 Colectomy and ileostomy NEC 
77171 Colectomy and side-to-side anastomosis of ileum to colon NEC 
X20XF Colectomy NEC 
7717z Colectomy: [other NOS] or [NEC] or [hemi- NEC] or [Rankin] 
Xa9Zk Colon and caecum operations 
XaA11 Colonic pouch operations 
X20XO Colostomy NEC 
X20XN Colostomy operation 
XE0DJ Construction of permanent colostomy 
Xa85G Construction of sigmoid colostomy 
XE0DI Construction of temporary colostomy 
76452 Creation defunctioning ileostomy (& [Brooke] or [split]) 
76450 Creation of continent ileostomy 
XE0D2 Creation of defunctioning ileostomy 
X20XR Creation of ileal pouch 
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XaB0q Creation of ileo-anal J-shaped pouch 
XaB0p Creation of ileo-anal pouch 
7645 Creation of ileostomy 
7645z Creation of ileostomy NOS 
XaFB4 Creation of loop ileostomy 
X20WX Creation of permanent ileostomy 
76451 Creation of temporary ileostomy 
XE0MS Excision large intestine (& colectomy) 
XaBAY Excision of caecum 
XaBC6 Excision of colocutaneous fistula 
XaA14 Excision of colonic pouch 
XE0D1 Excision of ileum NOS 
7716z Excision of sigmoid colon NOS 
Xa3u1 Excision small intestine 
Xa3ty Excision small intestine NOS 
7712z Extended excision of right hemicolon NOS 
X20XH Extended left hemicolectomy 
7712 Extended right hemicolectomy 
77121 Extended right hemicolectomy and anastomosis ileum to colon 
77122 Extended right hemicolectomy and anastomosis NEC 
77120 Extended right hemicolectomy and end-to-end anastomosis 
XaA10 Extended right hemicolectomy and ileostomy 
77123 Extended right hemicolectomy and ileostomy HFQ 
X20XE Hemicolectomy NEC 
YaaPj Ileal resection and ileostomy 
YabAT Ileal resection sample 
76403 Ileectomy and anastomosis of ileum to colon 
76403 Ileectomy and anastomosis of ileum to colon 
76402 Ileectomy and anastomosis of ileum to ileum 
XaB9j Ileectomy and ileostomy 
Xa9Tw Ileectomy NEC 
Y21hD Ileocaecal resection 
YahIf Ileocolic resection 
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Xa858 Ileostomy operation 
XE0D0 Ileum operations 
764z. Ileum operations NOS 
7632 Jejunostomy operations 
763.. Jejunum operations 
XaBAc Laparoscopic sigmoid colectomy 
XaBAd Laparoscopic transverse colectomy 
XaZVW Laparoscopically assisted right hemicolectomy 
XaBAe Laparoscopic-assist right hemicolectomy (?AND/OR[colectomy]) 
7715 Left hemicolectomy 
7715 Left hemicolectomy 
77151 Left hemicolectomy & end-to-end anastomosis colon to colon 
77152 Left hemicolectomy and anastomosis NEC 
77154 Left hemicolectomy and exteriorisation of bowel NEC 
77153 Left hemicolectomy and ileostomy however further qualified 
XaFzV Left hemicolectomy with anastomosis 
XaFzW Left hemicolectomy with stoma 
77150 Left hemicolectomy+end to end anastomosis of colon to rectum 
7717 Other excision of colon 
XE0DD Other excision of colon NOS 
7713 Other excision of right hemicolon 
7713z Other excision of right hemicolon NOS 
XE0DH Other exteriorisation of colon 
XE0DM Other exteriorisation of colon NOS 
771Rz Other operation on colon NOS 
764Bz Other operation on ileum NOS 
771R. Other operations on colon 
XE0D6 Other operations on ileum 
XE0D3 Other specified creation of ileostomy 
7640y Other specified excision of ileum 
764y. Other specified operations on ileum 
7717y Other specified other excision of colon 
7713y Other specified other excision of right hemicolon 
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7648y Other specified other open operation on ileum 
771Ry Other specified other operation on colon 
XaMM1 Other specified subtotal excision of colon 
7711y Other specified total excision of colon 
7710y Other specified total excision of colon and rectum 
77101 Panproc/colec 
XE0DA Panproctocolectomy anast ileum to anus & pouch creation HFQ 
77102 Panproctocolectomy and anastomosis of ileum to anus NEC 
77102 Panproctocolectomy and anastomosis of ileum to anus NEC 
77100 Panproctocolectomy and ileostomy 
Xa9U1 Parks panproctocolectomy 
Xa9Zi Partial colectomy 
XE0MW Partial colectomy (& sigmoid) 
77175 Partial colectomy NEC 
Xa7vg Partial jejunectomy 
76304 Partial jejunectomy and anastomosis of duodenum to colon 
76303 Partial jejunectomy and anastomosis of jejunum to ileum 
YaoCv Perineal resection rectum HFQ 
7710 Proctocolectomy 
7710 Proctocolectomy 
77103 Proctocolectomy NEC 
77103 Proctocolectomy NEC 
YMKgo Rectum-abdominoperin resection 
XS7fq Repair of colon 
XaB4f Repair of ileum 
XaBDA Repair of perforated colon 
XaB4e Repair of small intestine 
Yaonr Resection of ileo-colic anast 
Y21dr Resection of ileum 
7640 Resection of ileum 
Y21dg Resection of jejunum 
7630 Resection of jejunum 
YaaHp Resection of small intestine 
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YaaDQ Resection of terminal ileum 
XaB19 Resection of terminal ileum 
X20XQ Restorative proctocolectomy 
X20XI Right hemicolectomy 
77131 Right hemicolectomy & side-to-side anast ileum-transv colon 
77132 Right hemicolectomy and anastomosis NEC 
XaFzS Right hemicolectomy and anastomosis of ileum to colon 
77133 Right hemicolectomy and ileostomy however further qualified 
77130 Right hemicolectomy+end to end anastomosis of ileum to colon 
77130 Right hemicolectomy+end to end anastomosis of ileum to colon 
Yae6r Salvage AP resection of rectum 
X20XM Segmental colectomy 
X20Wd Segmental excision of small intestine 
7716 Sigmoid colectomy 
77160 Sigmoid colectomy & end-to-end anastomosis ileum to rectum 
77162 Sigmoid colectomy and anastomosis NEC 
77161 Sigmoid colectomy and anastomosis of colon to rectum 
XaBC1 Sigmoid colectomy and colostomy 
77164 Sigmoid colectomy and exteriorisation of bowel NEC 
XaBBq Sigmoid colectomy and ileostomy 
77163 Sigmoid colectomy and ileostomy however further qualified 
XaFzX Sigmoid colectomy with anastomosis 
XaFzY Sigmoid colectomy with stoma 
YaVc0 Small bowel resection 
764.. Small intestine operations (& ileum) 
76481 Strictureplasty of ileum 
XaL6I Sub ex colon rectum creation colon pouch anastom colon anus 
XaL6K Subtot exc colon creation colonic pouch anastom colon rectum 
X20XG Subtotal colectomy 
XaFzR Subtotal colectomy with anastomosis 
XaBC2 Subtotal colectomy with ileorectal anastomosis 
XaBBy Subtotal colectomy with ileosigmoid anastomosis 
XaMM2 Subtotal excision of colon NOS 
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YabAW Terminal ileum resection sample 
7711 Total colectomy 
77111 Total colectomy 
XaBCE Total colectomy 
XaBCH Total colectomy 
77110 Total colectomy & ileo-rectal anastomosis (& Hampton) 
XE0DB Total colectomy and anastomosis of ileum to rectum 
XaBCD Total colectomy and ileostomy 
77112 Total colectomy and ileostomy NEC 
7710z Total excision of colon and rectum NOS 
7710z Total excision of colon and rectum NOS 
7711z Total excision of colon NOS 
7714 Transverse colectomy 
77142 Transverse colectomy and anastomosis NEC 
77141 Transverse colectomy and anastomosis of ileum to colon 
XaBBm Transverse colectomy and ileostomy 
77143 Transverse colectomy and ileostomy HFQ 
XaFzT Transverse colectomy with anastomosis 
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Appendix 4 Documentation for the validation 
study of the ResearchOne database. Includes 
ethical approvals, patient information sheet, consent 
form and GP letter. 
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Patient 
information sheet 
Version 6 
IRAS - 196065 
Date 16/02/2016 
 
Validation of the SystmOne Primary Care Database for the use in healthcare research. 
A study to compare general practice records with hospital medical records for patients with 
inflammatory bowel disease. 
 
Chief Investigator – Dr Nick Burr, Specialist Registrar in Gastroenterology. Leeds Teaching Hospitals 
NHS Trust. 
 
1. Invitation 
 
You are invited to take part in this study for people with inflammatory bowel disease treated 
at Leeds Teaching Hospitals NHS Trust. The investigators want to know if the data held in 
medical records at the hospital in Leeds is similar to information held by your General 
Practitioner on their computer system. Before you decide to take part in this study it is 
important for you to understand why the research is being done and what it will involve. 
Please take time to read the following information carefully. Talk to others about the study if 
you wish. Please ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
2. What is the purpose of this study and why have I been chosen? 
 
The purpose of this study is to determine whether the information held on hospital records is 
the same as the information held on General Practice computer system databases. This is very 
important as General Practice databases can be extremely useful in conducting research 
studies into the long term effects of diseases and medications. It is very important that the 
data held on these databases is accurate before conducting the research studies.  
 
You have been selected to take part as you have a condition called inflammatory bowel 
disease. We will compare the diagnosis records of inflammatory bowel disease from Leeds 
Teaching Hospital with your GP records to see if the information is consistent. The information 
will contain no personal details and only the records related to your inflammatory bowel 
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disease diagnosis will be used. We will assign an anonymous, unique number to your record 
after the data has been combined to ensure you cannot be identified.  
 
3. Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you do decide to take part in the study, 
you will be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part, you are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the standard 
of care you receive. 
 
4. What will happen to me if I continue to take part?  
 
If you decide to take part in this study we will compare your medical records from the hospital 
with your General Practitioner’s medical records. We will do this by using your NHS number, 
which is a unique number already assigned to you. The same number is used on your GP 
medical records. It is important for you to know that we will not ask for any other information 
from your GP records other than those listed below.  
 
• Type of Inflammatory bowel disease. 
• Date of inflammatory bowel disease diagnosis. 
• Admission to hospital for a complication of inflammatory bowel disease. 
• Flare-up of your inflammatory bowel disease. 
• Any operation for your inflammatory bowel disease. 
 
Please note that we will not use this information for any other purpose than to check whether 
the information on the GP record is similar to that recorded in hospital medical records. Your 
information will not be shared, or made available to anyone not involved with this study. If 
you want more information then please contact a member of the study team: 
  
• Email - nick.burr@nhs.net. 
• Tel – (0113) 206 8691 
 
5. Will my taking part in this study be kept confidential?  
 
If you join the study, some parts of your medical records and the data collected for the study 
will be looked at by authorised persons from the research team. Nowadays all studies are 
monitored and audited by the study sponsor (University of Leeds) or by external government 
agencies. All will have a duty of confidentiality to you as a research participant and nothing 
that could reveal your identity will be disclosed outside the research site. Your medical 
information will all be held on secure, password protected computers at Leeds University. 
Your study files that undergo statistical analysis will be anonymised. Research publications 
that arise from this study will never contain any personal or identifiable details about you. 
Your data will be kept in a secure location at the University of Leeds for 5 years after the study 
has completed in line with European Guidelines after which point they will be destroyed. 
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6. What are the potential disadvantages of taking part? 
 
We do not envisage any disadvantages in taking part in this study. 
 
7. What are the potential benefits of taking part 
 
Taking part in this study will give credibility to the use of the ResearchOne database for 
healthcare research. This will be of benefits to patients and their clinicians as this resource 
has the potential to provide important information on the long-term consequences of 
diseases and medical treatments. 
 
8. Involvement of the general practitioner/family doctor (GP)  
 
We will notify your general practitioner that you are taking part in this study. 
 
9. Expenses and payments. 
 
Participation in this study will not cost you anything, nor will you be paid. 
 
10. Who is organising and funding the research and where was it reviewed?  
 
The study is being conducted within this institution by Dr Nick Burr, Specialist registrar within 
the gastroenterology department at Leeds teaching Hospitals NHS Trust. The study has been 
designed by a group of inflammatory bowel disease researchers. The study is being co-
coordinated by the University of Leeds. This study was given a favourable ethical opinion for 
conduct in the NHS by the National research ethics service. The conduct of this study at Leeds 
Teaching Hospitals has been authorised. If you have any complaints or concerns about the 
conduct of this research study, please discuss this with a member of the research team. If you 
are not satisfied, please contact the Patient Advisory and Liaison Service (Trust PALS). 
• Tel: (0113) 2066261 - Available during normal working hours only (9:00am to 4:30pm 
Monday to Friday). 
• Tel: (0113) 2067168 - For queries outside of normal working hours, please leave a 
voicemail. 
• E mail: patientexperience.leedsth@nhs.net 
        
11.  How will the results of the research be made available to me? 
 
After completion on the study we will produce a summary of the study findings which can be 
obtained by contacting the principal investigator. 
• Email - nick.burr@nhs.net. 
• Tel – (0113) 206 8691 
- 172  
 
Thank you for taking the time to consider this study. 
A copy of this information sheet and signed consent form will be given to you to keep. 
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Version 1 
Date 14.01.2015 
IRAS - 196065 
 
Dear Doctor. 
RE: Validation of the SystmOne primary care database for the use in healthcare research. 
 
Patient Name and DOB  
 
I am writing to inform you that your patient has agreed to participate in the above clinical trial at 
(Leeds Teaching Hospitals NHS Trust). This study is to validate the use of SystmOne primary care 
research database. This will improve the quality and applicability of this resource for healthcare 
research. To perform this study we will compare medical records from hospital outpatient clinics with 
that held on SystmOne.  
I have enclosed a copy of the Patient Information Sheet for your reference, however if you have any 
queries or require further information please contact Dr N Burr, Gastroenterology SpR Leeds Teaching 
Hospitals NHS Trust, nick.burr@nhs.net.  Tel – 0113 206 8691. 
 
Yours sincerely, 
 
Dr Nick Burr 
 
Encs: Patient Information Sheet, version 5 date 29/12/15  
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Board reviews 
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